The Lancet Commission on Malaria Eradication which recently published its report states that eradication of the mosquito-borne disease is possible by 2050. The commission, however, warns that while over 100 countries have managed to eradicate malaria, a chance of resurgence and re-establishment is still possible.

According to the Lancet Commission, in India, the malaria vector, Anopheles stephensi, has a suitable environment for breeding which means incidence of the disease in urban areas is quite high.

Notably, in 2017, there were a total of 219 million malaria cases in 86 countries, a decline from 262 million cases, and 839,000 malaria deaths in 2001. Out of the 219 million cases reported in 2017, 9.6 million were in India.

According to the Lancet commission, three important tools are necessary in the worlds attempt at eliminating malaria by 2050. These include rapid diagnostic tests, artemisinin-based combination therapy, and long lasting insecticide-treated nets.

Apart from these, IT, molecular methods for diagnosis and surveillance, and a new drug for Plasmodium vivax malaria will act as catalysts for eradication as well.

India follows the recommendations of World Health Organization (WHO)'s Global Technical Strategy for Malaria to eradicate the mosquito-borne disease. However, improper waste management, lack of municipal water supply infrastructure, etc, results in breeding facilitation of the Anopheles mosquito.

The out of pocket (OOP) burden, according to the commission is undesirable, forcing families to forego necessary care and causing medical impoverishment.

According to the Commission, India must invest a lot more in making malaria prevention and treatment tools more affordable and accessible for its citizens.

Speaking about the same, Dr Shailja Singh, Associate Professor at Special Centre for Molecular Medicine, JNU, says, that generalised policies will not work in case of India because the nation in itself is so diverse, and so are the Plasmodium parasites that affect its people.

According to her, to achieve complete eradication, firstly, a large scale surveillance to capture the diverse nature of malaria in India is needed. Secondly, a mass campaignlike in the case of poliocan also help in eradication processes.

The Lancet Commission further notes that eradication of the mosquito will not only reduce mortality, but will also be a financial win for nations, as according to a WHO report, it will result in an estimated gain in GDP of USD 238 billion, which would be a lot higher than the cost of eradicating itUSD 35 billion.

Get the best of News18 delivered to your inbox - subscribe to News18 Daybreak. Follow News18.com on Twitter, Instagram, Facebook, Telegram, TikTok and on YouTube, and stay in the know with what's happening in the world around you in real time.

More:

Lancet Commission Lists Three Tools for Effectively Zapping Malaria - News18

Bioinformatics involves the development and application of novel informatics techniques in the field of biology. It improves the methods of storing, organizing, retrieving and analyzing biological data. Major activity in bioinformatics is to develop software tools in order to generate useful biological knowledge database. In molecular biology, bioinformatics techniques such as signal processing allow extraction of useful results from large amount of raw data. In the field of genetics it helps in sequencing, annotating genomes and to observe mutations. Bioinformatics study acts a biological literature and developmental data bank for biology related data.

Similarly, biomedical informatics is an emerging discipline which defines the study of inventions and implementation of structures, algorithms to improve communication, understanding and managing the medical information. The National Center for Toxicological Research (NCTR) conducts research in bioinformatics and chemo informatics. The bioinformatics tools were created for analysis and integration of genomics, proteomics, metabolomics datasets and transcriptomics.

The growth of global medical bioinformatics market is driven by increasing initiatives and funding, use of bioinformatics in drug discovery and biomarkers. The market is expected to offer opportunities with the introduction and adoption of upcoming technologies such as cloud computing and other sequencing technologies. The global medical bioinformatics market can be segmented by tools approved from Food and Drug Administration (FDA) or European Federation for Medical informatics (EFMI) for further research process.

Medical Bioinformatics market is based on the tools, application and end users.

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/medical-bioinformatics-market.html

The global medical bioinformatics market can be segmented based on types of tools and the list of bioinformatics tools approved by FDA are as follows: Array Track: DNA microarray data management, mining, analysis, and interpretation software Estrogenic Activity Database (EADB): Comprehensive set of estrogenic activity data Endocrine Disruptor Knowledge Base (EDKB): Scientific resources for estrogen and androgen activity of potential endocrine disruptor chemicals Decision Forest: Novel pattern-recognition method for analysis of data from microarray experiments, proteomics research, and predictive toxicology AtBioNet: Integrated PPI (protein-protein interaction) Network Analysis Tool for Systems Biology and Biomarker Discovery Mold2: Software that generates molecular descriptors from two-dimensional structures NCTR Liver Cancer Database (NCTRlcdb): Database of 999 chemicals with assigned liver-toxicity classifications to facilitate the construction of cleaner and better carcinogenicity models approved by FDA and other organizations SNPTrack: Integrated solution for the management, analysis, and interpretation of genetic association study data Microarray/Sequencing Quality Control (MAQC/SEQC): Project to develop microarray quality control metrics and thresholds

The global medical bioinformatics market can be segmented by application as follows: Molecular Medicine Personalized Medicine Preventive Medicine

The global medical bioinformatics market can be segmented by end user as follows: Pharmaceutical Companies Hospitals Academic institutes Universities

Medical bioinformatics market is segmented into five major regions: North America, Europe, Latin America, Asia Pacific, and Rest of World. North America leads the market followed by the European nations in terms of revenue. Globally, the medical bioinformatics market growth is expected to increase with the demand in development of generic drug development and mode of sequencing the genes in order to have prevalence from various diseases. In 2015, Department of Biomedical Informatics was inaugurated at Harvard Medical School. This was initiated in order to bring quantitative methods and technological development to biomedicine engineering research. According to Harvard Medical School, Department of Biomedical Informatics (DBMI) and research associates planned to break the wall of autism by detecting the disorder in newborns using the same standard of testing device used to check for hearing impairment. According to Food and Drug Administration, collaboration with National Center for Toxicological Research has driven the demand and use of bioinformatics tools such as predicting patient-specific treatment outcomes with in silico tools. Latin America and Asia Pacific regions are anticipated to be the emerging markets in the global medical bioinformatics market during the forecast period. The effective guidelines from EFMI reports the promotion of high standard application and development in medical bioinformatics. Increase in patient population base and rising disease incidences in the Asia Pacific region is expected to fuel the use of bioinformatics tools for research and tests, which is projected to propel the demand in global medical bioinformatics market in the forecast period.

The key players in the global medical bioinformatics market develop bioinformatics tools, and software which is used in drug designing, sequencing methods. Some of the top players in the global medical bioinformatics market are Optra HEALTH, Affymetrix, Inc., Thermo Fisher Scientific Inc., Illumina, Inc., QIAGEN, Paraxel, Station X and others.

Request Brochure of this report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16382&source=atm

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis

The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) Eastern Europe (Poland and Russia) Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand) Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request For Discount On This Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=16382&source=atm

Read the original here:

Medical Bioinformatics Market 2017 Global Forecasts Analysis, Company Profiles, Competitive Landscape and Key Regions 2030 - Rapid News Network

Hair-loss during chemotherapy for cancer patients could soon become a thing of the past, thanks to new breakthrough research at The University of Manchester.

Scientists from the Centre for Dermatology Research, based in Manchester, have been working on reducing arguably one of the most psychological source of distress in cancer therapy induced hair-loss.

Taxanes, substances that widely used as chemotherapy agents in treating patients with lung or breast carcinoma, are believed to induce hair-loss as a powerful side-effect.

Research conducted by Doctor Talveen Purba and his colleagues, is believed to have found a way to prevent hair follicles from being damaged by the chemical taxanes, in the process of treating the malign formation in the body.

As the scientists explained in the journal EMBO Molecular Medicine, they have explored the proprieties of CDK4/6 inhibitors a new class of drug. These are presumed to block cell division and are medically approved as being the future in chemotherapy.

The lead coordinator of the study, Dr Talveen Purba stated that even though it might seem counter-intuitive at first, they found that DK4/6 inhibitors can be used temporarily to halt cell division without promoting additional toxic effects in the hair follicle.

Dr Purba further explained that when they bathed human scalp hair follicles in a CDK4/6 inhibitors solution they became less affected by the effects of taxanes. It analysed that the most vulnerable to taxanes were the specialised dividing cells which are located at the very base of the hair follicle, and the stem cells from which they arise. For that reason, they started an investigation on how to protect these particular cells from undesired chemotherapy effects but in such a way that malign cells are still eradicated successfully.

Their ultimate goal for the future is to develop externally applicable medicines that will complement existing preventive approaches for cancer treatment-induced hair loss.

Dr Purba emphasised the importance of this study, as there are still uncertainties when it comes to why some people lose more hair than others while in chemo treatment, and why some drug combinations produce more damage than others. This study is aimed at revealing those aspects as well.

He added: We need time to further develop approaches like this to not only prevent hair loss but promote hair follicle regeneration in patients who have already lost their hair due to chemotherapy.

The researchers behind the study highlighted the fact that more exploration in the topic area is desperately needed in this field of cancer research, which is currently highly underfunded. Patients, too, have been impatiently waiting for a pharmacological breakthrough when it comes to chemo-induced hair damage as they feel that hair-loss, especially in women, affects them the most.

The study has recently attracted a vast amount of attention, with many people eager to hear the outcomes.

Originally posted here:

UoM scientists' breakthrough for cancer hair-loss - The Mancunion

KARACHI: Federal Minister for Education and Professional Training, Shafqat Mahmood here on Wednesday called upon all stakeholders to play their role in turning education sector into free of politics with major focus on up-gradation of standard and quality of the courses and training offered to the children and youth of the country.

Inaugurating the National Institute of Virology at the Dr. Panjwani Center for Molecular Medicine and Drug Research (PCMD), University of Karachi, he said said the government was trying to unite all provinces on one point of education as this sector should be free from politics.

He pointed out that the government would steadily enforce a unified education system in the country to mitigate class differences between rich and poor classes.

The Minister for Education and Professional Training mentioned that the federal education ministry was working on many projects to enhance the quality of learning in all faculties and that the federal government has allocated Rs.59 billion for the higher the education sector.

The government was said to had taken major step towards introducing a uniform syllabus in the country.

With the regard to Virology Lab inaugurated by him, Shafqat Mahmood expressed his pleasure that a world class institution was focused towards understanding the causes of the viral diseases and expressed his confidence that it will play a key role in the prevention and treatment of viral disease in the country.

Emergence of several viral diseases in the last two decades, such as Dengue hemorrhagic fever, Zika, Chikungunya, and Congo fever has challenged the existing healthcare system of the country, he said appreciating that the virology research center was the first of its type using state-of-the-art technologies conduct scientific investigation on viral and other diseases.

On the occasion Vice-Chancellor University of Karachi Prof. Dr. Khalid Mehmood Iraqi, Prof. Dr. Atta ur Rahman, Chairman of the Prime Ministers National Task Force on Science and Technology, Director ICCBS Prof. Dr. Muhammad Iqbal Choudhary, and Chairman H.E.J. Foundation Aziz Latif Jamal also expressed their views.

Prof. Atta ur Rahman said that significant investments worth billions of rupees were being made in a multitude of projects related to the industry, agriculture, artificial intelligence, nanotechnology, industrial biotechnology, space sciences etc.

Prof. Khalid Mehmood Iraqi said that establishment of this world class institute was a key step forward towards the capacity building in the field of virology in Pakistan.

He pointed out that the building of the new institute was equipped with most modern tools, and facilities for frontier research in this important field of virology.

Post Views: 0

See the article here:

Shafqat Mahmood against politics in education sector - Business Recorder

Education should be free from politics, says Shafqat Mahmood

While inaugurating the National Institute of Virology at the Dr Panjwani Centre for Molecular Medicine and Drug Research (PCMD), Karachi University, on Wednesday, Federal Minister for Education and Professional Training Shafqat Mahmood said the government was trying to unite all provinces on one point of education as this sector should be free from politics.

He said the government would steadily enforce a unified education system in the country to mitigate class differences between rich and poor classes. He informed the participants that the federal education ministry was working on many projects to enhance the quality of education in all faculties of education.

The federal government had allocated Rs59 billion for the higher education sector, he said, adding that government had taken a major step towards introducing a uniform syllabus in the country.

On the occasion, Karachi University Vice-Chancellor Prof Dr Khalid Mehmood Iraqi, Prof Dr Atta ur Rahman, chairman of the Prime Ministers National Task Force on Science and Technology, Director ICCBS Prof Dr Muhammad Iqbal Choudhary, and Chairman HEJ Foundation Aziz Latif Jamal were also present.

I am pleased that a world-class institution to work on understanding the causes of the viral diseases has been inaugurated today, which I am confident will play a key role in the prevention and treatment of viral disease in the country, he said while talking about the newly established research centre.

The emergence of several viral diseases in the last two decades, such as dengue haemorrhagic fever, Zika, Chikungunya and Congo fever, had challenged the existing healthcare system of the country, he said.

The virology research centre, the first of its type, owned the state-of-the-art technologies for cutting-edge instruments to conduct scientific investigation on viral and other diseases. Addressing the audience, Prof Atta ur Rahman said significant investments worth billions of rupees were being made in a multitude of projects related to the industry, agriculture, artificial intelligence, nanotechnology, industrial biotechnology, space sciences etc.

Talking about the prominence of the ICCBS, he said that this internationally renowned research establishment owned four major aspects, which included its quality faculty, uppermost trained technicians, bright students, and public-private partnership.

Prof Khalid Mehmood Iraqi said that establishment of this world-class institute was a key step forward towards the capacity building in the field of virology in Pakistan. He pointed out that the state-of-the-art building of the new institute was equipped with most modern tools and facilities for frontier research in this important field of virology.

Prof Iqbal Choudhary said that the virology research centre, the first of its type, owned the state-of-the-art technologies for cutting-edge instruments to conduct a scientific investigation on viral and other diseases to contribute knowledge policy and practise and engage in capacity development for improved public health in Pakistan.

He said one the highest prevalence of hepatitis in Pakistan was causing considerable mortality and morbidity to people, and adversely affecting the national economic revival. Polio, non-existing in the world, had become a matter of national esteem for Pakistan, he said.

A message of Nadira Panjwani, chairperson of Dr Panjwani Memorial Trust, was read out by an official. In her message, she welcomed the federal minister and other participants in the ceremony, and said that the establishment of the virology research centre was yet another milestone for her organisation. It was, by all means, an essential need for the countrys healthcare infrastructure, she added.

Saman Aziz Jamal, in her speech, said that the HEJ Foundation had established three world-class science institutions at the ICCBS, apart from providing continuous help to the HEJ scientists, as well as establishing several industry-related laboratories. The most recent contribution of the foundation was the establishment of the Latif Ebrahim Jamal Nanotechnology Research Institute to be inaugurated soon, she maintained.

See more here:

Education should be free from politics, says Shafqat Mahmood - The News International

Flu shots can be hard to sell to the public. Even a run-of-the-mill influenza infection can be debilitating to otherwise healthy people, and lethal to those who are elderly or frail, so vaccinations are important. The problem is that flu vaccines deliver inconsistent performance. In a good season, were up to 60% effectiveness, but in bad, mismatched years it can be as low as 10% or 20%, says Barney Graham, deputy director of the Vaccine Research Center at the US National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Maryland.

Current flu vaccines provide protection only against the strains they have been matched to, so a universal flu vaccine that provides broader protection against most influenza viruses has been a long-standing dream. The 2009 swine-flu pandemic, which caught the public-health community off guard and claimed the lives of as many as half-a-million people worldwide, gave the issue new urgency.

The 2009 pandemic made it obvious and clear that we didnt have good enough solutions for influenza vaccines, says Graham. We knew the virus, but we werent able to make enough vaccine quickly enough. More-effective manufacturing is one solutionbut a single inoculation that protects against both seasonal and emerging strains would have much greater impact.

Fortunately, the timing of the pandemic coincided with great progress in the development of technologies for investigating the human response to influenza. Around 2008 or 2009, people started finding a few broadly neutralizing antibodies against the influenza virus, says Ian Wilson, a structural biologist specializing in vaccine development at Scripps Research Institute in La Jolla, California. Once people started looking, many more were discovered.

Now, around 100 years after the Spanish flu pandemic of 1918 that killed about 50 million people, multiple universal-vaccine programmes are demonstrating promise in both preclinical and clinical testing. But it remains to be seen whether any will ultimately deliver the broad protection that clinicians seek.

Peter Palese, a microbiologist at the Icahn School of Medicine at Mount Sinai in New York City, believes that todays flu vaccines come in for too much criticism. They are fairly good vaccines but theyre not perfect, he says. The main problem, he adds, is that they elicit a focused immune response against a moving target.

Humans are affected by two main types of influenza. Influenza A and B can both contribute to seasonal flu, but some influenza A subtypes preferentially infect animal hosts. Sometimes these subtypes abruptly acquire the ability to infect humans, leading to pandemics such as the one in 2009. Each year the seasonal flu vaccine is designed to cover two strains each of influenza A and B, based on the publichealth communitys best informed guess about which strains will be dominant that year.

Every influenza virus is studded with hundreds of molecular structures formed by a multifunctional protein called haemagglutinin. Haemagglutinin helps the virus to bind and penetrate host cells. It comprises a bulky head attached to the virus by a slender stalk. Most of the immune response is targeted at the head because it is highly exposed, but there is also evidence that the head contains features that preferentially elicit a strong antibody response.

There are structured loops, and antibodies easily recognize loops that stick out like that, explains James Crowe, director of the Vanderbilt Vaccine Center in Nashville, Tennessee. Unfortunately, these immunodominant elements are also highly variable between strains.

Influenza A viruses are particularly diverse. They are classified by numbers based on the subtype of haemagglutinin (H) protein and a second viral protein known as neuraminidase (N), with even greater strain variation observed among those subtypes. For example, the 2009 pandemic arose from a new strain of the H1N1 subtype. The extent of haemagglutinin variability means that poor strain selection can leave recipients largely unprotectedand even a good vaccine offers limited protection against future strains. In two years, the virus can change again so we can get re-infected and get disease, says Palese.

Further complicating the quest for a universal flu vaccine is the fact that our immune system is strongly biased by its earliest encounters with influenza through a phenomenon called imprintingor, as it has been dubbed, original antigenic sin. This means that individuals have a strong antibody response to viruses with molecular features shared by the strain encountered during their first exposure, but they essentially start from scratch when exposed to distantly related strains for the first time. Its not that you cannot see the second virusits just like youre a baby and youre seeing it for the first time, says Crowe.

Imprinting is a double-edged sword because early exposure to the right strain could theoretically produce far-reaching and vigorous protection in response to vaccination. But if a childs first influenza encounter is with a relatively unusual or atypical strain, vaccination might prove less effective in terms of rousing broadly protective immunity.

A vaccine that focuses the immune response on a more stable target on the virus could overcome the problem of viral diversity. Researchers have known that such targets existed for decades. In 1983, Palese and his colleagues determined that the haemagglutinin stalk domain is so similar between strains that antibodies can recognize specific physical features, known as epitopes, of haemagglutinin proteins from multiple influenza subtypes. Unfortunately, the stalk is something of an immunological wallflower, overshadowed by the influence of the head. We have engineered epitopes into the stalk and the same epitopes into the head, and we get a much better response to epitopes in the head, says Palese. But immunity can still emerge naturally in some cases, and a series of stalk-specific antibodies were isolated from human donors in 2008 and 2009.

More recently, several research groups have devised multiple vaccine strategies for selectively provoking a stem-specific response. Grahams team at NIAID, for example, undertook a painstaking process of protein engineering a standalone version of the stem from an H1 influenza virus. It took us about seven or eight years to engineer it and stabilize it enough to maintain the right surfaces and structures, says Graham. The researchers subsequently generated nanoparticles displaying multiple copies of these engineered stems and showed1 that these could generate strong protection against entirely different subtypes of influenza A, such as H5at least in animal models. This vaccine design is now undergoing a phase I clinical trial and could in principle confer protection against many of the most prominent pandemic virus subtypes. A newer haemagglutinin stem construct developed by NIAID could lead to even broader protection against the remaining subtypes.

Palese and Florian Krammer, a virologist who is also at Mount Sinai, have developed an alternative approach to stimulating stemspecific immunity. They have generated multiple influenza viruses with chimaeric haemagglutinin proteins in which the same stalk domain is paired with various exotic head domains from virus subtypes that primarily infect birds and are therefore unlikely to trigger an imprinting-biased response in humans. If you then revaccinate with a vaccine that has the same stalk but a completely different head, the immune memory against the stalk could be boosted, explains Krammer.

This approach uses the entire virus particle, creating the potential to elicit parallel immune recognition of other influenza antigens. On the basis of promising evidence of crossprotection against diverse influenza A subtypes in animals, the Mount Sinai team is now conducting phase I trials to explore the vaccines safety and effectiveness in humans.

Inspired by the discovery of cross-protective stalk antibodies in the wild, several research groups have been casting the net wider to find more such molecules. We use all kinds of donorspeople who are actively sick, people who have recovered from avian influenza, or well go to other countries to find donors with exposure to unusual strains, says Crowe. After isolating the antibody-producing B cells from these individuals, researchers can comprehensively profile the specific influenza targets that elicit a natural immune response and identify antibodies that might have broad infectionneutralizing capabilities.

These studies have revealed that even in the variable head domain of haemagglutinin there are structural elements that are consistent across influenza subtypes. In 2012, researchers at Scripps and Janssens Crucell Vaccine Institute in Leiden, the Netherlands, identified2 an antibody called CR9114, which exhibited unprecedented breadth of recognition. That could actually bind to both influenza A and influenza B, says Wilson, who helped characterize the antibody. This antibody is now being used to identify target epitopes on haemagglutinin that can be exploited to achieve far-reaching virus neutralization for both prevention and treatment.

In some cases these searches have revealed unexpected vulnerabilities in the virus. Haemagglutinin normally assembles into highly stable complexes of three closely coupled molecules, but Crowe and Wilson discovered3 this year that these trimers occasionally open up to expose a weak point to which antibodies can bind, potentially thwarting infection by a wide range of influenza A viruses. This trimer interface is a whole new universal flu epitope, and everybodys going crazy about it, says Crowe. Its not even clear how it works, but it clearly works in animals.

Much of the variability between influenza viruses is only skin deep. Probe more deeply within the virus particle and you find greater similarity in the essential proteins. These are beyond the reach of antibodies but they can be recognized by T cellsan element of the immune system that can target and eliminate influenza-infected cells, which present peptide signatures of their viral intruders.

So far, antibodies have been the primary focus of the vaccine community because they represent a crucial first line of defence against circulating virus particles, but T cells provide critical protection by containing infection once it is under way. People get exposed and infected every two or three years on average, says Sarah Gilbert, who heads vaccine development at the University of Oxfords Jenner Institute, UK. The vast majority of these infections are either asymptomatic or mild, she says, and the reason is that people have a T-cell response thats strong enough to protect them.

In general, eliciting a truly protective T-cell response entails reawakening memory T cells that were formed in the aftermath of a previous exposure. Gilberts team uses a crippled vaccinia virus that can infect human cells and that synthesizes two different immunitystimulating influenza proteins but is incapable of further replication. With a single dose, we saw a boost in pre-existing T-cell responses of between eight- and tenfold in humans, says Gilbert. She adds that the target proteins are 90% identical across influenza A viruses, offering the potential for broad protection against pandemic strains.

Gilberts vaccine is undergoing two phase II trials under the guidance of Vaccitech, a company she co-founded in Oxford. A potent T-cell response also seems to contribute to the apparent cross-protection offered by a replication- defective flu vaccine from FluGen, based in Madison, Wisconsin, which has reported success in a recent phase II clinical trial.

Even with several promising series of human trials under way, the road to the clinic remains fraught with difficulties. Mice are often used for early studies of vaccine preclinical development but Palese points out that they are not a natural reservoir for the influenza virus. Many researchers therefore quickly switch to using ferrets to test their vaccine candidates, because they are broadly susceptible to influenza and are physiologically more like humans in that ferrets have a longer respiratory tract than mice. Both species are short-lived, however, making it difficult to study the effects of a vaccine over many rounds of influenza exposure.

Gilbert has started working on pigs in collaboration with the Pirbright Institute near Woking, UK. This long-lived species could serve as both a useful test case and an important beneficiary for vaccines. The upper respiratory tract of the pig is very similar to the human and they tend to get infected with the same viruses, she says. And there is a need for flu vaccines in pigsthe 2009 H1N1 pandemic virus is thought to have come from pigs.

Krammer has also used pigs as a model but says their large size makes them difficult to use routinely in research. Moreover, he is hesitant about drawing too many conclusions from any animal model: You can use them to down-select candidates and for safety, but with universal influenza vaccines, the ultimate animal model is Homo sapiens.

The ultimate proof for any flu vaccine is protection against disease in clinical trials. But for a putative universal vaccine, such testing is more complicated. A growing number of groups are using human challenge trials, in which healthy volunteers are deliberately exposed to a particular influenza strain after vaccination. This approach allows for faster trials with smaller cohorts and defined exposure conditionslowering the trial costand it also allows researchers to hand-pick the viruses they wish to protect against.

But challenge trials also have their critics. Its not a natural infection. You have to inoculate people with a million or even ten million virus particles, says Krammer, and it doesnt seem to work like a natural infection. These trials also leave out very young and very old people, which are the groups most vulnerable to flu.

Another problem is that the US Food and Drug Administration still requires a real-world trial before giving approval, and these are difficult and costly. They require thousands of participants to ensure that a sufficient number of people are exposed to flu, and they must span several seasons to demonstrate efficacy against multiple virus strains or subtypes.

Many academic researchers say that even embarking on a clinical trial can pose a nearly insurmountable challenge, because it requires access to sophisticated production facilities that meet the high bar of good manufacturing standards. Even if its a simple construct, were talking about at least a year to make it and a cost of approximately US$1 million to $2 million, says Krammer. A few major companies such as GlaxoSmithKline and Janssen have made these investments, but obtaining that much funding from either public or private bodies is far from easy. Gilbert struggled for five years to obtain funding before launching her company, which raised the capital needed to bring her labs vaccine programme into phase II trials.

More investment may be on the way. In the past few years, both NIAID and the US Biomedical Advanced Research and Development Authority have prioritized the development of a universal vaccine, and the Bill & Melinda Gates Foundation has joined forces with governmental and non-governmental organizations to form the Global Funders Consortium for Universal Influenza Vaccine Development.

The vaccines now being developed promise much broader protection than current seasonal shots but fall well short of being truly universal. The World Health Organization (WHO) still sees considerable value in such vaccines, and has called for a vaccine that prevents severe disease from all forms of influenza A by 2027, which would prevent pandemics. But Krammer points out that seasonal influenza B infections can also inflict a serious death toll, and both he and Palese have focused their sites on true universality. I think the WHO is making the bar too low, says Palese. We really should be trying to aim high.

Universal protection need not entail eliminating all traces of influenza virus but simply providing sufficient immunity to minimize the symptoms of infection. Even achieving that more modest goal will probably require a multipronged attack. Stem antibodies contribute to protection but are probably not sufficient for very potent protection, says Crowe. They would be just part of the scheme.

Indeed, Gilbert is exploring the potential of a broader immunological assault that melds the Mount Sinai groups chimaeric stem vaccine with her teams vaccinia technique. At least in mice, she says, combining these two approaches was better than either alone.

A greater understanding of the human immune system and its response to infection could inform smarter vaccination strategies. In May 2019, the US National Institutes of Health awarded $35 million to an international team of researchers to profile the immunity of young children in the years after their initial exposure to influenza, providing the deepest insights yet into the imprinting process.

Their findings could help vaccine designers figure out the best way to rewire the immune system while it remains malleable. And that, says Crowe, could be a game-changer. You could envision doing a universal vaccination as your first exposure, with beneficial imprinting for the rest of your life, he says.

Michael Eisenstein is a science writer in Philadelphia.

See original here:

Towards a universal flu vaccine - Scientific American

From the irises in our eyes to the shape of our ears to our fingerprints, no two humans on eartheven identical twinsare alike. So when our bodies become sick or injured, applying a one-size-fits-all, trial-and-error treatment for whatever ails us may be a good solution for a majority of patients, but it is not the best for all of them.

Enter personalized medicine. This revolutionary medical model is pushing the boundaries of traditional practice by creating new, precise treatments; reducing the need for expensive tests; and flagging risk factors that enable earlier diagnoses for everything from cancer to asthma to Alzheimers. Researchers in Arizona are at the forefront of this innovation, which combines genetic research, molecular profiling, nanotechnology, and other cutting-edge medical practices.

Across the states private sector and public universities, work is being done on a number of fronts to diagnose and treat cancer patients with methods tailored to their individual needs in the most effective way. At the University of Arizonas (UA) Bio5 Institute, biotech engineers have created a tiny pillbox that floats through the bloodstream, andon cuedelivers medicine to cancerous cells, avoiding healthy ones. Researchers at startup GT Medical Technologies Inc. of Tempe developed a tinysmaller than a square inchcollagen tile that can deliver radiation to tumor cells that were missed by surgery. Celgenes Abraxane is made in Arizona. The injectable drug treats pancreatic, breast, and certain types of lung cancers.

Just as important, cancer diagnostic tools are the subject of much research in Arizona. Arizona State University is home to the Virginia G. Piper Center for Personalized Diagnostics, which uses a plasmid repository to develop early warnings for those at risk of major illnesses. Tucson-based tumor profiling company HTG Molecular Diagnostics technology allows the genetic profiling of a tumor using a much smaller sample of the tumor than is required by traditional technology. Roche Tissue Diagnostics (formerly Ventana Medical Systems, founded by UA pathologist Dr. Thomas Grogan) provides more than 250 cancer tests through state-of-the-art automated testing. In addition to diagnostics, the company works with pharmaceutical companies to find relevant therapies for the patients its diagnosed. Caris Life Sciencess services include molecular profiling for genetics and pathology for early detection of cancer and other complex diseases. This global companys Life Sciences primary lab and the Caris Research Institute are located in Phoenix, which it calls the ideal location for a continuous service laboratory because of the predictable weather patterns and limited exposure to extreme weather events and natural disasters.

Arizona has also become ground zero for Alzheimers research. This important study is a collaborative effort of public and private institutions working together to decode the genetic makeup of patients, delay the onset, treat the symptoms, and save lives. The Arizona Alzheimers Consortium member institutions include Arizona State University, Barrow Neurological Institute, Mayo Clinic Arizona, Banner Sun Health Research Institute, the Translational Genomics Research Institute (TGen), the University of Arizona, and Banner Alzheimers Institute. The Barrow Neurological Institute at St. Josephs Hospital is home to cutting-edge imaging technology and clinical and research partnerships with world-class neurologists and neurosurgeons. Banner Sun Health Research Institute hosts the National Institutes of Health-designated Arizona Alzheimers Disease Center in the retirement community of Sun City. The consortium, through more than 5,000 publications and 1,000 research grants, has proposed new Alzheimers treatments, supported research through data-sharing and collaboration, and facilitated $1.5 billion in investments in Alzheimers research.

It has been said often in the [Arizona State House] Health Committee, the brain that will cure Alzheimers will be an Arizona brain, said Arizona State Representative Heather Carter.

Another stellar example of the importance of public-private collaboration in advancing personalized medicine is Phoenix-based TGen, a nonprofit research institute that began in 2002 with $100 million from Arizona public- and private-sector investors. TGen researchers work on employing genetic discoveries to develop smarter diagnostics and targeted therapies. Today, the TGen biomedical campus is an integral piece of a statewide bioscience initiative with faculty who contribute to biomedical discoveries and the quality of health care for Arizona residents.

While clinicians and researchers in Arizona continue to achieve medical breakthroughs in personalized medicine, information technology professionals at many of these same institutions are advancing telemedicinethe delivery of health care through inexpensive portable devices that allow patients to conduct their own lab tests and download results.

The Mayo Clinic first rolled out its stroke telemedicine program in Arizona in 2007. Neurologists trained in blood vessel conditions, along with neurosurgeons and neuroradiologists, work as a team with emergency medicine doctors and staff at remote sites to treat stroke patients. The stroke telemedicine program is now on Mayo campuses in Florida and Minnesota and treats over 1,500 patients annually at 28 remote hospital sites. Banner Health Systems, called a trendsetter with a robust history employing this technology by HealthLeaders, connects with patients and bedside care teams across the state to monitor best practices and measure clinical outcomes.

Medical records, too, can be accessed with ease, thanks to telemedicine. GlobalMed, based in Scottsdale, provides access anywhere to patient data and medical images. Their hardware, software, and cloud solutions are used in 55 countries.

Education in telemedicine, which started as a pilot program at the University of Arizona College of Medicine in 1995, is now part of the curriculum that provides services, distance learning, informatics training, and telemedicine technology assessment capabilities to cities and towns across the state. Recognized as one of the premier programs at the college, its received numerous awards at the national level for its research and innovations. UA is also the home of the Southwest Telehealth Resource Center, which works with organizations in five states to coordinate technology and other resources for telemedicine programs. ASUs Project HoneyBee, Northern Arizona Universitys Center for Bioengineering Innovation, and NAUs Health Research Institute are also working on developments in telemedicine.

If the recent announcement by Mesa startup Myndshft is any indication of the future of telemedicine, expect phenomenal growth. Two Arizona residents founded the company, which specializes in blockchain and artificial intelligence in health care, in 2015. It expects to grow its staff to 100 by the end of 2019.

The concentration of biotech innovators in Arizona means the state is well ahead of the game in both personalized medicine and telemedicine. Arizona medical experts, researchers, entrepreneurs, designers, and manufacturers all are key players in developing new devices and facilitating these advancements to improve health care outcomes for those not just in the state but also around the world.

Learn more at azcommerce.com.

See the original post here:

Arizona: The New Frontier in Technology and Health Care - SPONSOR CONTENT FROM ARIZONA COMMERCE AUTHORITY - Harvard Business Review

A breakthrough has been made in preventing hair loss in cancer patients.

Doctors say that losing their hair while undergoing chemo adds to the distress of breast cancer patients.

Taxane-based chemotherapy drugs are an important tool for fighting cancer, but their toxicity damages hair follicles and can cause permanent hair loss.

To try and prevent hair loss, University of Manchester researchers have exploited a newer class of targeted cancer drugs.

The so-called CDK4/6 inhibitors block the division of cancerous cells while limiting the damage to hair follicles.

Study lead author Dr Talveen Purba said: Although at first this seems counter-intuitive, we found that CDK4/6 inhibitors can be used temporarily to halt cell division without promoting additional toxic effects in the hair follicle.

When we bathed organ-cultured human scalp hair follicles in CDK4/6 inhibitors, the hair follicles were much less susceptible to the damaging effects of taxanes.

Researchers hope this approach could lead to new treatments to prevent chemotherapy-induced hair loss, which can be traumatic for cancer patients.

They added patients have waited too long to see real breakthroughs in hair loss prevention because this field of cancer treatment is lamentably under-funded.

In the first stage of the research, Dr Purbas team examined exactly how hair follicles responded to taxane chemotherapy.

They found that the specialised dividing cells at the base of the hair follicle were critical for producing hair.

They also discovered that the area most vulnerable to the chemotherapy side effects was the stem cells which hair grows from.

Dr Purba added: We must protect these cells most from undesired chemotherapy effects but so that the cancer does not profit from it.

The team hope their work will help to develop externally applicable medicines to slow cell division in the scalp hair follicles to reduce hair damage.

Such medicines could complement and enhance existing preventive approaches including scalp cooling devices.

The researchers highlighted that more work is desperately needed in the field to deliver real breakthroughs for cancer patients and to find out why some suffer greater hair loss than others.

Dr Purba said: Despite the fact that taxanes have been used in the clinic for decades, and have long been known to cause hair loss, were only now scratching the surface of how they damage the human hair follicle.

We need time to further develop approaches like this to not only prevent hair loss, but promote hair follicle regeneration in patients who have already lost their hair due to chemotherapy.

The study was published in the EMBO Molecular Medicine.

Visit link:

Breakthrough in bid to prevent hair loss in cancer patients - The London Economic

Image credit: Pixabay.

A new study has shown the power of genetic testing to pick out the best drugs for children with cancer to extend and improve their lives signalling a new era of precision medicine for young patients.

The pilot including more than 200 children found that half had gene mutations that are targetable by adult cancer drugs that are either available as standard treatment or via clinical trials.

Although few children on the study went on to receive adult drugs, those who did receive targeted therapies had significant benefits.

But the study also laid bare the regulatory and funding barriers to children receiving the newest drugs, as only 7 per cent of those with targetable mutations were able to access the appropriate adult drug.

The study was led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, and offered genetic testing of tumours to children as part of a clinical trial. Some 20 additional hospitals around the UK participated by sending childrens biopsies in for testing.

The research ispublished in the European Journal of Cancer today (Thursday) and was primarily funded by the parent-led charity Christophers Smileand the NIHR Biomedical Research Centreat The Royal Marsden and The Institute of Cancer Research (ICR).

Researchers used a gene panel test to read the DNA sequence of 91 genes that drive cancers growth and spread from 223 childrens tumour biopsies looking for potentially targetable mutations.

Solid tumours such as those of the brain, central nervous system, bone and muscle are rare but have much worse survival rates than childrens blood cancers such as leukaemia. Surgery is often not possible and treatment is limited to blunt instrument chemotherapies.

The researchers first validated the panel test, showing it to be than more than 99 per cent sensitive at picking up the 91 mutations, even with just 50 nanograms of DNA which is around 1,000 times less than the weight of a grain of table salt.

Using the test, they found 51 per cent of tumour samples tested had mutations that could be targeted by adult cancer drugs.

The most common potentially treatable mutations were in the genes ATRX, CDKN2A and CTNNB1 which were each found in 12 childrens tumours. MYCN mutations were found in 11 tumours and PI3K3CA mutations in 10 tumours.

Three children had BRAF gene mutations which are common in melanoma skin cancers and can be treated using a combination of the drugs dabrafenib and trametinib.

Using these melanoma drugs, one of the children had their brain tumour held in check for 13 months before developing resistance. Another was on the drug for nine months with no progression of disease. The third child couldnt tolerate the combination but had a response to dabrafenib for 15 months.

We are building a new state-of-the-art drug discovery centre to develop a new generation of drugs that will make the difference to the lives of millions of people with cancer.

Find out more

But there are still challenges to overcome, since the majority of children with targetable mutations didnt receive adult drugs because there was no trial available for the drug in children, they were unable to access the drug on the NHS or they were too ill to receive an experimental treatment by the time they were tested.

For eight of the patients, there were samples available at diagnosis and after treatment and in six of those, testing revealed that the cancer had acquired new mutations as it evolved in response to treatment. That highlights the need to take an additional biopsy at relapse to search for targetable mutations.

For 12 of the children, the researchers were also able to test for cancer gene mutations in DNA released from tumours into the bloodstream from a blood sample. They found blood tests picked up almost all of the mutations found in the tumour, and in some cases they also found extra mutations which were not detected in the tumour region biopsied.

In future work the researchers will use serial blood tests to monitor how tumours evolve in response to therapies which will be particularly useful in hard-to-biopsy tumours.

Additionally, for children with brain tumours, the researchers are now looking at using samples of cerebral-spinal fluid to find drug targets. Although lumbar punctures are invasive, they are less so than a brain biopsy.

Study author Dr Sally George, Clinical Research Fellow at the ICR and Consultant Paediatric Oncologist at The Royal Marsden, said:

Children deserve the very best cancer treatments, so they can live as long as possible and as well as possible. We desperately need better, more intelligently designed treatments which can give children longer with their families with fewer side effects.

By testing tumours for specific gene mutations, we have shown its possible to identify new smarter, kinder treatment options for children, which may potentially give these patients much longer with their families after conventional therapies have failed.

But our study also exposes the desperately frustrating barriers that children still face in receiving new treatments barriers which lie in the regulations controlling how drugs for children are developed and approved.

Study leader Professor Louis Chesler, Professor of Paediatric Cancer Biology at the ICR, and Consultant at The Royal Marsden, said:

Our study has demonstrated that we have the scientific knowledge and technology to get children access to state-of-the-art testing and treatments. And because our testing currently only assesses a focused set of well-known and clinically meaningful mutations, it is more practical, faster and more cost-effective than looking at the whole genome.

In future, I want to be able to treat more children whose tumours have these targetable mutations with better drugs, as currently not all children have access. But gathering the molecular data is the first practical step to making this possible. This data, and more that we are continuing to collect, will be good evidence to more clearly guide use of the most appropriate drug for each child.

It is also very important that we extend very robust and detailed testing to children at time of diagnosis, so we can more accurately classify and treat these cancers in the first place. We will also be looking at the utility of the approaches for detecting cancer relapse, a very important area where we currently have few tools to anticipate what treatments may be required with adequate time to do so.

September gives us a chance to highlight the incredible research that goes on at the ICR, but we continue to work tirelessly with our parent charity partners all year round to keep making the discoveries that we hope will one day defeat childrens cancer.

Find out more

Dr Mike Hubank, Head of Clinical Genomics at The Royal Marsden and Reader in Translational Genomics at the ICR, said:

The next steps for testing will be to look at using liquid biopsies to detect targetable tumour mutations without having to rely on invasive biopsies to get the information.

Our early results, presented here, show that we can detect more mutations in blood than we do in conventional biopsies. It is probably in the blood that we get a more complete picture of the whole tumour, and not just the small part of the tumour that was removed for testing. Blood-based testing will also allow us to monitor tumour response to treatment and may be able to detect relapses early, offering the possibility of finely tuned, personalised treatments in the future.

Karen Capel is the founder and trustee of UK childrens cancer charity Christophers Smile, who funded the development of the test. Karen and her husband Kevin have campaigned tirelessly to improve the treatment for children with cancer after their son Christopher died from medulloblastoma in 2008. Karen said:

When our son died there was no biological information available to doctors about individual childrens tumours. There is an urgent unmet need to provide new treatments for those children diagnosed with the most aggressive and hard-to-treat cancers.

This test Professor Chesler and colleagues at the ICR developed is a first for children. We believe gene sequencing is the key foundation stone in enabling personalised medicine, and it will help to bring new treatments for children a step closer.

Building on the foundations of the sequencing test, blood tests could provide critical information for any child from diagnosis throughout their treatment and into remission opening the door for additional, continued or changed treatments. We are determined to fight for these liquid biopsies to become standard of care at the earliest opportunity.

As well as the main funding from Christophers Smile and the NIHR, the study was also supported by Children with Cancer UK, Cancer Research UK, Abbies Fund,Rosetrees Trust, the KiCa Fund, Rocheand The Brain Tumour Charity.

The Royal Marsden Cancer Charity supports Dr Sally Georges work, and funds Dr Mike Hubanks work through a generous donation from Her Highness Sheikha Jawaher Bint Mohammed Al Qasimi of Sharjah. The Royal Marsden Cancer Charity also funds The Royal Marsdens Oak Paediatric Drug Development Unit.

Read more from the original source:

Study signals new era of precision medicine for children with cancer - The Institute of Cancer Research

EXPERTS ADVISORY

A national dialogue about fat shaming and other aspects of obesity has been touched off in recent days by late-night television host James Corden, and his response to comments by fellow television host Bill Maher.

Corden, who openly discussed his own struggle with being overweight, referenced research from a University of Michigan team in a monologue that has gone viral on social media.

In addition to the researchers behind that study, many other U-M scientists, health care researchers and clinicians work to understand the risk factors that contribute to obesity, the roots of weight issues at the molecular and genetic level, and the outcomes from weight-loss strategies ranging from exercise to bariatric surgery.

These experts are available to comment to media:

Kim Eagle

Kim Eagle, M.D. A cardiologist and co-director of the U-M Frankel Cardiovascular Center, co-led the 2016 study that Corden mentioned on his show. Using data from Massachusetts, it found that childhood obesity rates were highest among public schoolchildren living in the poorest areas, and that racial and ethnic differences in childhood obesity rates went away when family income was factored in (more information).

Eagle also leads Project Healthy Schools, a partnership between Michigan Medicine and community organizations aimed at reducing childhood obesity through in-school action.

Contact: Michigan Medicine Department of Communication, 734-764-2220

Martin Myers

Martin Myers Jr., M.D., Ph.D. Cordens monologue also referenced the importance of leptin, a hormone involved in metabolism and obesity. Leptin is the focus of work by Myers, a Medical School professor who is the director of MDiabetes, which brings together members of the U-M research community who study metabolism and diabetes.

His research focuses on the processes that enable the body to respond normally to insulin, and how problems in these pathways contribute to the development of insulin resistance and diabetes. His laboratory specifically concentrates on the crucial role played by nerve centers in the unconscious part of the brainwhat Myers calls glycemic control centersthat regulate the bodys ability to respond to insulin.

Contact: Michigan Medicine Department of Communication, 734-764-2220

Katherine Bauer

Katherine Bauer, Ph.D., M.S., assistant professor of nutritional sciences at the School of Public Health, is an epidemiologist whose research focuses on how social factors such as families and schools influence childrens nutrition and growth. Her work has specifically focused on the harms of family weight talk and teasing, and she is currently studying how blame directed at parents of children of higher weight impacts families.

Contact: kwbauer@umich.edu

Kendrin Sonneville

Kendrin Sonneville, assistant professor of nutritional sciences at the School of Public Health, is a registered dietitian, behavioral scientist and public health researcher whose research focuses on the prevention of eating disorders among children, adolescents and young adults. She uses a weight-inclusive framework to study how to promote health and well-being without inadvertently increasing body dissatisfaction, disordered eating and weight stigma.

Weight stigma and fat-shaming are pervasive across society, including within health care settings, Sonneville said. Weight stigma harms people with larger bodies and should not be used as a health promotion tool.

Contact: 734-763-8789, kendrins@umich.edu

Randy Seely

Randy Seeley, Ph.D., director of the Michigan Nutrition Obesity Research Center, oversees an effort to bring together U-M researchers focused on prevention and treatment of obesity at all levels. It is one of only 12 obesity research centers funded by the National Institutes of Health. Seeleys own work at the Medical School focuses on understanding the way the metabolism changes after bariatric surgery.

Contact: Michigan Medicine Department of Communication, 734-764-2220

Ling Qi

Ling Qi, Ph.D. The complicated relationship between obesity, metabolism and the immune system is the specialty for Qi, a professor of physiology at the Medical School. Qis team recently used a discovery about this relationship to spur mice to produce more insulin (more information).

Contact: Michigan Medicine Department of Communication, 734-764-2220

Amir Ghaferi

Amir Ghaferi, M.D., M.S. is a bariatric surgeon and health care researcher at Michigan Medicine and VA Ann Arbor Healthcare System. He directs the Michigan Bariatric Surgery Collaborative, which pools data from obesity-related surgery programs at 42 Michigan hospitals to fuel improvements in care, research and evidence-based decision tools to help people with obesity decide if bariatric surgery is the best option for them.

Contact: Michigan Medicine Department of Communication, 734-764-2220

Huda Akil

Huda Akil, Ph.D., a neuroscientist who co-directs the Molecular and Behavioral Neuroscience Institute, recently published findings about the roots of overeating deep in the brain. She and her colleagues discovery, made in mice, shows that the brain has molecules that act as both brakes and a gas pedal to govern eating, and explored how the two interact (more information).

Contact: Michigan Medicine Department of Communication, 734-764-2220

Roger Cone

Roger Cone, Ph.D. is director of the U-M Life Sciences Institute and vice provost and director of the U-M Biosciences Initiative. He is an obesity researcher who studies how the brain controls body weight and regulates energy balance. His lab has identified how two key receptors in the brain affect energy balanceand the receptors central roles in disease cachexia, anorexia nervosa and the most common cause of syndromic obesity in humans. His labs findings have served as the basis for developing setmelanotide, a new drug to treat syndromic obesity.

Contact: U-M Life Sciences Institute Communications, 734-615-6228

Continued here:

U-M obesity experts available to comment on complexity of overcoming national epidemic - University of Michigan News

Perpetual expansion of application areas of biotechnology in the fields, such as, disease diagnosis and forensic research is attracting the attention of health care professionals. Bioinformatics is used for management, storage, and standardization of information obtained from research and development in biotechnology, life sciences, and biopharmaceutical industries. The global bioinformatics services market has experienced tremendous growth in the past decade due to factors such as advancement in technology, expanding application of information technology in health care, and increasing demand for data management tools in life sciences and biotechnology research sectors. Major factors influencing the growth of this market are increasing research and development activities in the field of biotechnology, drug discovery, and biopharmaceuticals. In addition, increase in government initiatives also boosts the growth of the biotechnology market globally. Bioinformatics is widely used in research and development in the biotechnology and biopharmaceutical industries. Research and development activities involve significant investments and thus, small and medium-sized companies face difficulties in investing on analytical software. In order to reduce the cost of research and development process, manufacturers are focusing on development of web-based software solutions, wherein researchers need to make marginal investment in analytical software. In addition, web-based analytical software does not require large storage or data handling capacity. Thus, owing to the mentioned factors, demand for web-based analytical software is expected to rise in the near future. Therefore, web-based offerings in bioinformatics show potential growth opportunities for players operating in this market. Bioinformatics techniques demand skilled manpower to derive accurate results. Installation and upgrade to sophisticated tools or platforms in clinical laboratories demand for high investment in training of the staff so that they can efficiently use the systems. Lack of skilled personnel is a key factor restricting the adoption of sophisticated and high-end biotechnology processes.

The global bioinformatics services market can be segmented based on service type, application, end-user, and region. In terms of service type, the bioinformatics services market can be categorized into sequencing services, database and management services, data analysis services, and other services. Bioinformatics has eased the process of data analysis with various technological applications. Manufacturers are offering various services in order to overcome the shortage of skilled personnel in using bioinformatics tools and platforms. Data analysis is one of the vital operations performed by the bioinformatics service industry. High-end tools, such as, microarrays have been introduced to cater to the rising demand for customized data analysis. In terms of application, the bioinformatics services market can be classified into preventive medicine, molecular medicine, gene therapy, drug development, and others. Based on end-user, the bioinformatics services market can be segmented into academic and research institutes, pharmaceutical and biotechnology companies, hospitals and clinics, and others.

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/bioinformatics-services-market.html

In terms of region, the global bioinformatics services market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to continue its dominance in the global bioinformatics services market owing significant R&D expenditure, greater acceptance of technology advancements, and increase in investments for technological innovations in bioinformatics. Rise in drug discovery and development, coupled with increase in government initiatives toward funding of small and start-up companies in the biotechnology and life sciences industry, is a major factor expected to drive the bioinformatics services market in North America during the forecast period. The bioinformatics services market in major countries of Asia Pacific, such as India and China, is expected to grow rapidly during the forecast period. Government initiatives to boost the biotechnology sector is a prime driver of the bioinformatics services market in the region. Moreover, availability of skilled and qualified manpower at low cost, government support in setting up of manufacturing units, strategic acquisitions of local players, and currency difference benefits are expected to attract global bioinformatics manufacturers to Asia Pacific.

Key players operating in the global bioinformatics services market are Agilent Technologies, IBM Life Sciences, Qiagen N.V., Illumina Inc., Eurofins Scientific, Bruker Daltonics Inc., Perkinelmer Inc., Accelrys Inc., Life Technologies Corporation, and CD Genomics.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Request Brochure of this report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=46488&source=atm

The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis

The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) Eastern Europe (Poland and Russia) Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand) Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request For Discount On This Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=46488&source=atm

Go here to read the rest:

Bioinformatics Services Market Development Analysis 2017-2025 - Rapid News Network

Livestock antibiotic resistance

Most antibiotic use is for livestock, and it is growing with the increase in global demand for meat. It is unclear what the increase in demand for antibiotics means for the occurrence of drug resistance in animals and risk to humans. Van Boeckel et al. describe the global burden of antimicrobial resistance in animals on the basis of systematic reviews over the past 20 years (see the Perspective by Moore). There is a clear increase in the number of resistant bacterial strains occurring in chickens and pigs. The current study provides a much-needed baseline model for low- and middle-income countries and provides a one health perspective to which future data can be added.

Science, this issue p. eaaw1944; see also p. 1251

The global scale-up in demand for animal protein is the most notable dietary trend of our time. Since 2000, meat production has plateaued in high-income countries but has grown by 68%, 64%, and 40% in Asia, Africa, and South America, respectively. The transition to high-protein diets in low- and middle-income countries (LMICs) has been facilitated by the global expansion of intensive animal production systems in which antimicrobials are used routinely to maintain health and productivity. Globally, 73% of all antimicrobials sold on Earth are used in animals raised for food. A growing body of evidence has linked this practice with the rise of antimicrobial-resistant infections, not just in animals but also in humans. Beyond potentially serious consequences for public health, the reliance on antimicrobials to meet demand for animal protein is a likely threat to the sustainability of the livestock industry, and thus to the livelihood of farmers around the world.

In LMICs, trends in antimicrobial resistance (AMR) in animals are poorly documented. In the absence of systematic surveillance systems, point prevalence surveys represent a largely untapped source of information to map trends in AMR in animals. We use geospatial models to produce global maps of AMR in LMICs and give policy-makersor a future international panela baseline for monitoring AMR levels in animals and target interventions in the regions most affected by the rise of resistance.

We identified 901 point prevalence surveys from LMICs reporting AMR rates in animals for common indicator pathogens: Escherichia coli, Campylobacter spp., nontyphoidal Salmonella spp., and Staphylococcus aureus. From 2000 to 2018, the proportion of antimicrobial compounds with resistance higher than 50% (P50) increased from 0.15 to 0.41 in chickens and from 0.13 to 0.34 in pigs and plateaued between 0.12 and 0.23 in cattle. Global maps of AMR (available at resistancebank.org) show hotspots of resistance in northeastern India, northeastern China, northern Pakistan, Iran, eastern Turkey, the south coast of Brazil, Egypt, the Red River delta in Vietnam, and the areas surrounding Mexico City and Johannesburg. Areas where resistance is just starting to emerge are Kenya, Morocco, Uruguay, southern Brazil, central India, and southern China. Uncertainty in our predictions was greatest in the Andes, the Amazon region, West and Central Africa, the Tibetan plateau, Myanmar, and Indonesia. Dense geographical coverage of point prevalence surveys did not systematically correlate with the presence of hotspots of AMR, such as in Ethiopia, Thailand, Chhattisgarh (India), and Rio Grande do Sul (Brazil). The highest resistance rates were observed with the most commonly used classes of antimicrobials in animal production: tetracyclines, sulfonamides, and penicillins.

The portfolio of antimicrobials used to raise animals for food is rapidly getting depleted, with important consequences for animal health, farmers livelihoods, and potentially for human health. Regions affected by the highest levels of AMR should take immediate actions to preserve the efficacy of antimicrobials that are essential in human medicine by restricting their use in animal production. In some middle-income countries, particularly in South America, surveillance must be scaled up to match that of low-income African countries that are currently outperforming them despite more limited resources. Policy-makers coordinating the international response to AMR may consider sparing African countries from the most aggressive measures to restrict access to veterinary drugs, which may undermine livestock-based economic development and rightfully be perceived as unfair. However, in regions where resistance is starting to emerge, there is a window of opportunity to limit the rise of resistance by encouraging a transition to sustainable animal farming practices. High-income countries, where antimicrobials have been used on farms since the 1950s, should support this transitionfor example, through a global fund to subsidize improvement in farm-level biosafety and biosecurity.

The main article presents a map of antimicrobial resistance in animals in low- and middle-income countries where sales of veterinary antimicrobials remain largely unregulated. In this image, broilers are seen roaming freely outside of a family-owned farm in Kitwe, Zambia. [Photo: S. Jetha]

The global scale-up in demand for animal protein is the most notable dietary trend of our time. Antimicrobial consumption in animals is threefold that of humans and has enabled large-scale animal protein production. The consequences for the development of antimicrobial resistance in animals have received comparatively less attention than in humans. We analyzed 901 point prevalence surveys of pathogens in developing countries to map resistance in animals. China and India represented the largest hotspots of resistance, with new hotspots emerging in Brazil and Kenya. From 2000 to 2018, the proportion of antimicrobials showing resistance above 50% increased from 0.15 to 0.41 in chickens and from 0.13 to 0.34 in pigs. Escalating resistance in animals is anticipated to have important consequences for animal health and, eventually, for human health.

Antimicrobials have saved millions of human lives, yet the majority (73%) are used in animals raised for food (1). The large and increasing use of antimicrobials in animals is both an enabler and a consequence of the global scale-up in demand for animal protein. Since 2000, meat production has plateaued in high-income countries but has grown by 68%, 64%, and 40% in Africa, Asia, and South America, respectively (2). The transition to high-protein diets in low- and middle-income countries (LIMCs) has been facilitated by the global expansion of intensive animal production systems, in which antimicrobials are used routinely to maintain health and productivity (3). A growing body of evidence has linked this practice with antimicrobial-resistant infections not just in animals but also, in some cases, in humans (46). Although the majority of emerging infectious disease events have been associated with drug-resistant pathogens of zoonotic origins (7), antimicrobial resistance (AMR) in animals has received comparatively less attention than in humans.

In LMICs, trends in AMR in animals are poorly documented. Colombia is currently the only country that has publicly available surveillance data on AMR in animals (8). As in high-income countries, antimicrobials are used in LMICs to treat animals and as surrogates for good hygiene on farms. However, in LMICs, AMR levels could be exacerbated by lower biosecurity, less nutritious feed, and looser regulations on veterinary drugs (9). Conversely, in LMICs, AMR levels may also be reduced by less meat consumption and limited access to veterinary drugs in rural areas. Few studies have attempted to disentangle the effect of those factors and, thus far, expert opinion has prevailed over an evidence-based assessment of AMR in LMICs (10).

In 2017, The World Health Organization (WHO) called on its member states to reduce veterinary antimicrobial use (11, 12). Coordinating the global response to AMR requires epidemiological data to assess trends in AMR across regions. In human medicine, the WHOs Global Antimicrobial Resistance Surveillance System (GLASS) (13) has encouraged the adoption of a harmonized reporting framework, but there is no comparable framework for AMR in animals. Scandinavian countries have been at the forefront of monitoring AMR in animals, and Europe and the United States have adopted similar systems (14). However, in LMICs, similar surveillance systems are nascent at best, and building a globally harmonized surveillance system could take a long time. The challenge posed by AMR requires immediate action, and thus alternatives to systematic surveillance are needed to guide intervention based on the best evidence currently available.

In LMICs, point prevalence surveys are a largely untapped source of information with which to map trends in AMR in animals. Generating resistance maps from these surveys presents several challenges. First, surveys often differ in protocol, sample size, and the breakpoints used for antimicrobial susceptibility testing. Harmonizing these variations is a first step toward improving comparability. Second, because AMR affects many organisms, indicator organisms should be identified; the foodborne pathogens listed by the WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) are an ideal starting point (15). Third, because the problem of AMR affects many drug-pathogen combinations, it is difficult to communicate with policy-makers. Introducing composite metrics of resistance may help when summarizing global trends. Finally, the interpolation of epidemiological observations from data-rich regions to data-poor regions is inherently uncertain and could be improved using factors associated with AMR.

Species distribution modeling can identify such associations for predictive mapping, and the development of ensemble geospatial modeling (16) has helped to improve their accuracy.

In this study, we address these challenges to mapping AMR in animals in LMICs at 10-km resolution using point prevalence surveys of common foodborne pathogens. The maps summarize current knowledge and provide policymakers, or any future international panel (17), a baseline with which to monitor AMR levels in animals and to target interventions across regions.

We identified 901 point prevalence surveys reporting AMR rates in animals and food products in LMICs. Our analysis focused on resistance in Escherichia coli, Campylobacter spp., nontyphoidal Salmonella spp., and Staphylococcus aureus. The number of published surveys on resistance to these pathogens in LMICs increased from three in 2000 to 121 in 2018 and peaked at 156 per year in 2017. However, the number of surveys conducted during that period was uneven across regions (Fig. 1A): surveys from Asia (n = 509) exceeded the total for Africa and the Americas (n = 415). The number of surveys per country was not correlated with gross domestic product (GDP) per capita (Fig. 1B).

(A) Publications by continent. (B) Publications per capita versus GDP per capita; each country is designated by International Organization for Standardization (ISO3) country code.

In LMICs, from 2000 to 2018, the proportion of antimicrobial compounds with resistance higher than 50% (P50) increased from 0.15 to 0.41 in chickens and from 0.13 to 0.34 in pigs and plateaued between 0.12 to 0.23 in cattle (Fig. 2). Those trends were inferred from the average yearly increase in P50 (1.5%/year for chickens and 1.3%/year for pigs), weighted by the number of studies published each year (supplementary materials).

Proportion of antimicrobial compounds with resistance higher than 50% (P50) is shown. Solid lines indicate statistically significant (5% level) increases of P50 over time; shading indicates the number of surveys per year relative to total number of surveys per species.

In LMICs, resistance levels showed considerable geographic variations (see Fig. 3A and fig. S1 for country-level indexes). Regional hotspots (P50 > 0.4) of multidrug resistance were predicted in south and northeast India, northeast China, north Pakistan, Iran, Turkey, the south coast of Brazil, Egypt, the Red River delta in Vietnam, and the areas surrounding Mexico City and Johannesburg. Low P50 values were predicted in the rest of Africa, Mongolia, and western China. On the basis of maps of animal densities (fig. S2), we estimate that across LMICs, 9% [95% confidence interval (CI), 5 to 12%] of cattle, 18% (95% CI, 11 to 23%) of pigs, and 21% (95% CI, 11 to 28%) of chickens were raised in hotspots of AMR in 2013. For chickens, the percentage of birds raised in hotspots of resistance in each country exceeded the global average in China [38% (95% CI, 24 to 46%)], Egypt [38% (95% CI, 22 to 55%)], and Turkey [72% (95% CI, 41 to 81%)]. We also identified regions where AMR is starting to emerge by subtracting P50 from P10 (the proportion of antimicrobial compounds with resistance higher than 10%; Fig. 3C). In Kenya, Morocco, Uruguay, southern and eastern Brazil, central India, Iran, Chile, and southern China, the difference between P10 and P50 was high (>0.5), indicating that these regions are emerging AMR hotspots. Conversely, established hotspots of AMR where the difference between P10 and P50 was low (<0.1) included northeastern China, West Bengal, and Turkey.

(A) P50, the proportion of antimicrobial compounds with resistance higher than 50%. (B) 95% confidence intervals on P50 (supplementary materials). (C) Difference in the proportion of antimicrobials with 10% resistance and 50% resistance. Red areas indicate new hotspots of resistance to multiple drugs; blue areas are established hotspots. Maps are available at resistancebank.org.

The accuracy of the P50 maps (Fig. 3B) reflects the density of surveys for a region as well as the ability to associate the geographic distribution of P50 with environmental covariates using geospatial models (supplementary materials). All geospatial models had limited accuracies (areas under the curve, 0.674 to 0.68), but all identified the travel time to cities of 50,000 people as the leading factor associated with the geographic distribution of P50. Minimum annual temperature and percentage of irrigated land were also positively associated with P50 but had less influence (table S1).

Uncertainty in the map of P50 was high (95% CI > 0.3) in the Andes, the Amazon region, West and Central Africa, the Tibetan plateau, Myanmar, and Indonesia. Dense geographical coverage of surveys (>4 point prevalence surveys/100,000 km2) did not systematically correlate with high P50 values (Ethiopia; Thailand; Chhattisgarh, India; and Rio Grande do Sul, Brazil).

The highest resistance rates were observed in the most commonly used classes of antimicrobials in animal production (Fig. 4): tetracyclines, sulfonamides, and penicillins (1). Among antimicrobials considered critical to human medicine (18), the highest resistance rates were found for ciprofloxacin and erythromycin (20 to 60%) and moderate rates were found for third- and fourth-generation cephalosporins (10 to 40%). Other critically important antimicrobials, such as linezolid and gentamicin, were associated with lower resistance rates (<20%). AMR trends in LMICs were in agreement with the trends reported in Europe and the United States (14, 19) for tetracyclines, sulfonamides, and third- and fourth-generation cephalosporins, but differences also exist for quinolones and aminoglycosides.

Shown are resistance rates and number of surveys (n) by region. Transparency levels reflect sample sizes for each animal-pathogen combination (for drug acronyms, see supplementary text, protocol S1).

In E. coli and Salmonella spp., quinolone resistance in LMICs (20 to 60%) was comparable with European levels [59.8 to 64% (14)], but gentamycin resistance was higher in LMICs (5 to 38%) than in Europe (2.4 to 8.9%). The reverse situation was observed when comparing LMICs and the United States, where quinolone resistance is low (2.4 to 4.6%) and gentamycin resistance higher [22.1% and 41.3% for Salmonella and E. coli, respectively (19)]. In LMICs, high resistance in third- and fourth-generation cephalosporins in E. coli was high (~40%). Resistance to carbapenems was low in all host species in LMICs, as previously reported in animals (20). Asia and the Americas currently have the highest rate of colistin resistance (~18 to 40%).

In Campylobacter spp., in LMICs, the highest resistance rates were found for tetracycline (60%) and quinolones (60%). Tetracycline resistance was also the highest among all animals in the United States [49.1 to 100% (19)], but lower for quinolones in chickens (20%). Resistance to erythromycin was moderate (<30%) in LMICs but higher than in high-income countries (0.3 to 22% in the United States and 0 to 21.6% in Europe), indicating that erythromycin resistance genes [e.g., erm(B)] could be spreading more commonly on mobile genetic elements in LMICs.

Finally, for S. aureus, resistance rates across all antimicrobials were higher in Asia than in other regions. The highest rates were found for penicillin (40 to 80%), erythromycin (20 to 60%), tetracycline (20 to 60%), and oxacillin (20 to 60%). For S. aureus, unlike other pathogens, resistance rates among antibiotics (except for penicillin) varied greatly by region. Comparisons with high-income countries are limited, as few European countries reported resistance in S. aureus in 2016, and susceptibility testing was typically restricted to methicillin-resistant S. aureus, which has considerable variation in prevalence [0% in Irish cattle and chickens to 40 to 87% in Danish pigs (14)].

In most high-income countries, AMR has been monitored in animals for over 10 years (14). Here, we used point prevalence surveys to conduct a global assessment of the trends in AMR in animals in LMICs. A singular challenge in the epidemiology of AMR is to synthetize a problem involving multiple pathogens and compounds across different regions. We therefore introduced a summary metric of resistance, P50, which reflects the ability of veterinarians to provide effective treatment solutions. On the basis of the evidence assembled, P50 increased in LMICs from 0.15 to 0.41 (+173%) in chickens and from 0.13 to 0.34 (+161%) in pigs and plateaued between 0.12 and 0.23 in cattle. Rapid increases in AMR in chickens and pigs are consistent with the intensification of livestock operations for these species compared with cattle (21). The main consequence of those trends is a depletion of the portfolio of treatment solutions for sick animals. This loss has economic consequences for farmers because affordable antimicrobials are used as first-line treatment (22), and this could eventually be reflected in higher food prices.

The number of surveys supporting this first assessment is limited (n = 901) and heterogeneous across countries (fig. S3A). However, it enables us to draw inferences on large-scale trends in AMR (Fig. 3A). Globally, the percentage of animals raised in hotspots of AMR was limited (<20%), with the notable exception of chicken production in upper- to middle-income countries such as Turkey (72%) and Egypt (38%). These countries are also the first- and third-largest per-capita consumers of antimicrobials in human medicine among LMICs (23).

The largest hotspots of AMR in animals were in Asia, which is home to 56% of the worlds pigs and 54% of the chickens. In Asia, targeted interventions such as legislative action and subsidies to improve farm hygiene could reduce the need for antimicrobials in animal production (1), thereby preserving important drugs for human medicine and the treatment of sick animals. We identified hotspots for the emergence of AMR including central India and Kenya, where resistance to multiple drugs has appeared but not yet reached 50% (Fig. 3C). In these regions, meat consumption is still low and animal production is gradually intensifying. Here, there may be a window of opportunity to contain AMR by imposing strict hygiene standards in newly built farms. This approach could reduce the risk of the spread of resistant pathogens such as mcr-1carrying E. coli (6) that have emerged in regions where intensive meat production has been facilitated by enormous quantities of veterinary antimicrobials (1).

In Africa, resistance maps reveal the absence of major AMR hotspots, except for the Johannesburg metropolitan area. This suggests, on the basis of the regions surveyed, that Africa probably bears proportionately less of the current global burden of AMR than high- and upper- to middle-income countries. Policy-makers coordinating an international response to AMR might therefore spare Africa from the most aggressive measures, which may undermine livestock-based economic development and rightfully be perceived as unfair.

In the Americas, where the number of surveys was limited (Fig. 3B), the observed low AMR levels could reflect either good farming practices (low antimicrobial use) or the absence of surveys conducted in the areas most affected by AMR. Considering that Uruguay, Paraguay, Argentina, and Brazil are net meat exporters (2), it is of concern that little epidemiological surveillance of AMR is publicly available for these countries. Many low-income African countries have more point prevalence surveys per capita than middle-income countries in South America. Globally, the number of surveys per capita was not correlated with GDP per capita, suggesting that surveillance capacities are not solely driven by financial resources.

In this study, we stacked predictions from geospatial models to map P50 and P10 in LMICs. The moderate accuracy of these models reflects the challenge of associating the spatial distribution of AMR with environmental and socioeconomic factors (24). AMR in animals may be driven by factors known to influence antimicrobial use in humanssuch as cultural norms, the presence of drug manufacturers in the national market, or the density of health professionals (25)that could not be easily mapped from publicly available sources of information. The leading factor associated with the spatial distribution of P50 was the travel time to cities (26). Ease of access to providers of veterinary drugs may drive AMR, and hotspots appear to correspond to peri-urban environments where large farms supply affluent city dwellers. We also found a positive association between P50 and temperature. Evidence for a link with temperature in animals is less established than in humans (27), but it has been suggested that high temperature causes stress and conflicts in animals, thus increasing the risk of wounds that require preventive antimicrobial treatment (28). Finally, in Asia, 74% of P50 hotspots corresponded to areas previously identified for their projected increase in antimicrobial use (fig. S4). The relative influence of antimicrobial use on the spatial distribution of P50 was limited to 3.8% (table S1), but this association should be treated with caution given the scarcity of original data on antimicrobial use in LMICs (29).

We identified diverging patterns of resistance across combinations of pathogens and drugs. For S. aureus, geographic differences in AMR levels could be explained by sublineages carrying different SCCmec cassettes that are specific to certain regions (30). Of greater concern for public health is the presence of resistance to third- and fourth-generation cephalosporinscritically important antimicrobials for human medicineon all continents. In addition, the high levels of colistin resistance found in Asia suggest that regional spread may have been driven by plasmid-mediated resistance (6), as well as by the widespread use of this cheap antimicrobial. The recent Chinese ban on colistin (31), if enforced, may improve the situation. However, globally, progress may be undermined by the large quantities of colistin still used, including in some high-income countries. For quinolones, in LMICs, E. coli and Campylobacter had resistance levels comparable with European levels but considerably higher than in the United States, where quinolones were banned in poultry in 2005. Conversely, for Salmonella and E. coli, LMICs had substantially higher resistance to gentamycin than in Europe, where this compound is banned for use in poultry and cattle (32). These findings suggest that regional restrictions on the use of specific compounds are associated with lower AMR rates.

The uncertainty associated with interpolation of resistance rates is captured with confidence interval maps (Fig. 3B). However, there are additional sources of uncertainty. First, insufficient geographic coverage may lead to inaccurate spatial predictions, and local variations in AMR may not reflect ground truth. In this study, we attenuate the risk of overfitting geospatial models to local outliers using spatial cross-validation. Second, temporal variation in AMR over the period 20002018 was not accounted for. As more surveys become available, spatiotemporal, model-based geostatistics approaches could help to overcome this limitation. Third, in slaughterhouse surveys, most did not perform molecular typing longitudinally throughout the different processing stages, which would have enabled us to assess potential cross-contamination. Although cross-contamination may generally affect AMR rates, in the absence of international benchmarking, it is unknown whether it could systematically bias our result in any single country. Finally, our analysis raises renewed concerns about the pace of increase of AMR in animals, but it is beyond the scope of this study to draw conclusions about the intensity and directionality of transfer of AMR between animals and humans, which should be further investigated using robust genomics methods (33).

Point prevalence surveys are imperfect surrogates for surveillance networks. However, in the absence of systematic surveillance, maps have been useful to guide interventions against other diseases of global importance, such as malaria (34). In human medicine, point prevalence surveys of AMR in hospitals have generated snapshots of AMR across regions (35).

This initial assessment outlines three global priorities for action. First, our maps show regions that are poorly surveyed and where intensified sampling efforts could be most valuable. Second, our findings clearly indicate that the highest levels of AMR in animals are currently found in China and India. These countries should take immediate actions to preserve antimicrobials that are essential in human medicine by restricting their use in animal production. Third, high-income countries, where antimicrobials have been used on farms since the 1950s, should support the transition to sustainable animal production in LMICsfor example, through a global fund to subsidize improvements in farm-level biosafety and biosecurity (36).

T. P. Van Boeckel, J. Pires, R. Silvester, C. Zhao, J. Song, N. G. Criscuolo, M. Gilbert, S. Bonhoeffer, R. Laxminarayan, R code for: Global trends in antimicrobial resistance in animals in low- and middle-income countries, Zenodo (2019). doi:10.5281/zenodo.3354324

A. Getis, J. K. Ord, The analysis of spatial association by use of distance statistics, in Perspectives on Spatial Data Analysis (Springer, 2010), pp. 127145.

More here:

Global trends in antimicrobial resistance in animals in low- and middle-income countries - Science Magazine

Scientific Sessions Track 1: Molecular Medicine

Molecular medicine is a broad field which deals with the development of diseases at a molecular level and identifies fundamental molecular and genetic errors of disease and to develop molecular interventions to correct them. Molecular structures and mechanisms are described by Physical, chemical, biological, bioinformatics and medical techniques. Disease pathogenesis at the molecular or physiological level may lead to the design of specific tools for disease diagnosis, treatment, or prevention.

By understanding the genes, proteins, and other cellular molecules work molecular medicine develops ways to diagnose and treat disease. Molecular Medicine develops knowledge and skills in cellular and molecular biology.

Molecular diagnostics is a collection of techniques used to analyse an individual's genetic code and to identify biological markers in the genome and proteome. Molecular diagnostics apply molecular biology to see how cell express their genes to medical testing. For any successful application of gene therapy or biologic response modifiers, molecular diagnostics offers a great tool. Molecular diagnostics now provides most laboratory tests in infectious diseases, genetics, and an increasing number in oncology. Molecular diagnostics analyse a person's health at a molecular level by detecting specific sequences in deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) that may be related to disease

Molecular genetics employs methods of both molecular biology and genetics to study the structure, function and interactions among genes at a molecular level.

The study of chromosomes and gene expression of an organism can give an accurate and deep understanding of heredity, genetic variation, and mutations. Molecular Genetics and Genomics cover all areas on the latest research innovations, population genetics, gene function and expression and molecular genetics. Molecular genetics is concerned with the study of your favourite gene, genomics is concerned with studying all the genes. Molecular genomics is a critical component of the expanding database linking alterations of DNA and RNA with the disease, disease prognosis and therapeutic response.

Molecular oncology refers to the chemistry of cancer and tumours at the molecular scale and their development and application on molecularly targeted therapies.

Molecular Oncology studies especially the genetic alterations and their implications. Molecular Oncology focuses on new discoveries, approaches, as well as technical developments in basic, clinical and discovery-driven cancer research. It mainly focuses on advances in the understanding of disease processes leading to human tumour development. Molecular Oncology establishes novel concepts of clear clinical significance in diagnosis, prognosis and prevention strategies.

A biomarker is used as an indicator of the biological state. In routine clinical use Oncology biomarkers actually, make their way. A biological marker points to the presence of a disease, a physiological change, response to treatment, or a psychological condition.

Molecular biomarkers are used for various purposes including disease diagnosis and prognosis and assessment of treatment response. Over the last decade, there has been a significant increase in the number of drug labels containing information on molecular biomarkers. In most of the chronic diseases, biomarkers can confirm a difficult diagnosis or even make it possible in the first place.

Molecular biology is the study of biological activity between biomolecules in the various systems of a cell. It also includes the interactions between DNA, RNA, proteins and their biosynthesis as well as the regulation of these interactions.

Cellular and Molecular Biology majorly study the processes that occur within and between the body's cells. This includes genes, the way cells carry nutrients throughout the body, and how diseases attack healthy cells. The process of replication, transcription and translation of the genetic material are studied under Molecular biology. Cellular biology study cells, including their function, systems, structure and interactions with living organisms. These typically work in medical fields and are often focused on the treatment of disease.

Molecular pathology is the study of molecules within organs, tissues or bodily fluids. Molecular pathology is commonly used in the diagnosis of bone, soft tissue tumours, cancer and infectious diseases. The purpose of molecular pathology is to understand the mechanisms of disease by identifying molecular and pathway alterations. It is considered the heart of modern diagnostics and translational research. Molecular pathology studies and diagnose disease through the examination of genetic and molecular abnormalities. Molecular pathology and biomarkers are used to study molecular and genomic abnormalities in tissues for diagnostic and prognostic purposes. Molecular diagnosis is useful and sometimes necessary as an adjunct for diagnosis especially in morphologically or clinically unusual lesions.

Living things all are alike at the cellular and molecular level. The fundamental similarities between living organisms are explained by evolutionary theory. Major topics in molecular evolution concern the rates and impacts of single nucleotide changes, origins of new genes, the evolution of development, and ways that evolutionary forces influence genomic and phenotypic changes. Some of the key advances are quantitative estimates of both the diversity in populations and of evolutionary relationships, as well as improvements in theoretical understanding. There is an improved understanding of the function of proteins and much better models of the common patterns of development.

Advances in cell and molecular biology studies have revolutionized the diagnosis and treatment of many different diseases. It is considered as a modern Biotechnology concerned with understanding the Genetic Diagnosis, Molecular Diagnosis, Molecular Forensics.

People at the present day are facing serious global challenges in healthcare from emerging and re-emerging diseases. The availability of new sequencing methods, microarrays, microfluidics, biosensors, and biomarker assays has made a shift toward developing diagnostic platforms, which stimulates growth in the field regarding diagnosis, prognosis, and treatment, leading to improved outcomes and greater cost savings.

Much research is being done in foetal whole exome sequencing and is beginning to play a large role in miscarriage testing. With all this research and screening, clinicians and genetic counsellors need to keep abreast of these changes and guidelines in order to effectively care for patients.

The genetic cause of foetal abnormalities detected on ultrasound imaging and in high-risk families can be significantly identified and improved in Foetal diagnostic exome sequencing. Testing based on isolation of foetal cells from maternal blood would provide an attractive alternative to testing of cell-free DNA. An updated implementation of these different approaches will make lively discussion and insight into this field and is headed ways for researchers, test providers, clinicians and clinics to take these developments into consideration.

Point-of-care testing is medical diagnostic testing at the time and place of patient care. In Recent years there are tremendous advances in POCD due to innovations lab-on-a-chip technologies, and complementary technologies. Critical advances in POCD provides directions for future research. Point-of-care allows physicians and medical staff to accurately achieve real-time, lab-quality diagnostic results within minutes rather than hours. The global Point of Care diagnostic tests renders immediate results providing improved patient care in rural areas too. This factor has significantly impacted the market growth.

Clinical diagnostics is defined as diagnosis and treatment of human disease. Clinical diagnostics for a disease can be done by patient's complaints based on signs, symptoms and medical history rather than on laboratory examination or medical imaging. Clinical diagnostics is considered as an ever-changing field of medicine and research. In recent years Clinical diagnostics has become more exciting as advances in new techniques aid in fulfilling the potential of personalized medicine. Clinical research determines the safety and effectiveness of medications, devices, diagnostic products and treatments.

A monoclonal antibody (mAb) is originally produced by a single B-cell. Biosimilars are a lot complicated than small-molecule medicine and generics. In the past few years, monoclonal antibody drugs have dominated the world's largest biopharmaceutical drug sales, and in the coming years, monoclonal antibody drugs will continue to be the main force. Considering the huge profit margins and potential market, the monoclonal antibody-based therapeutics is the hot territory many pharmaceutical companies chases. This session will summarize the market in terms of therapeutic applications, type, and structure of mAbs, dominant companies, manufacturing locations, and emerging markets. These requirements would lead to greater development in the process and tighter quality controls during the production of biosimilar mAbs.

Infectious diseases are caused by pathogenic organisms such as viruses, bacteria, or fungus. Normally harmless but under certain conditions, they can be fatal and can cause death too. They can be spread from one person to another directly or indirectly. Infectious diseases are caused by infection-causing organisms that use the human body for surviving, reproducing and colonizing. These organisms are known as pathogens.

Antibiotics are used to treat bacterial infections;

Antiviral agents treat viral infections;

and

Antifungal agents treat fungal infections.

Next-generation sequencing (NGS) has revolutionised the study of genomics and molecular biology by allowing us to sequence DNA and RNA much more quickly and cheaply than the previously used Sanger sequencing. Next Generation Sequencing (NGS) relies on capillary electrophoresis. NGS although with shorter read lengths and less accuracy reduces the time that genome sequencing projects took with Sanger methods.

Thousands to millions of DNA molecules can be sequenced simultaneously by using Powerful Next Generation Sequencing (NGS) platform. By offering a high throughput option NGS is revolutionizing in fields such as personalized medicine, genetic diseases, and clinical diagnostics.

Immunogenicity is the ability of a particular substance induce a humoral and/or cell-mediated immune responses. An immune response can be potentially elicited by administering any substance into the human body.

Products which increase the potential of anti-drug antibodies include :

Therapeutic antibodies, enzyme therapies, peptides and combination products.

An immune response may also impact a drugs safety and efficacy. Assays should be designed in such a way that they provide sufficient sensitivity and are free from potential risks to the target patient population. By designing assays with these factors, it is possible to gather data about the strength and type of immune response that a drug may produce in humans.

Metagenomics is the study of genetic material recovered from environmental samples. Metagenomics could be an asset of analysis techniques comprising several connected approaches and ways. We tend to anticipate that metagenomics can complement and stimulate analysis on people and their genomes.

Metagenomics represents a brand-new approach in exceedingly genomic analysis. Metagenomic libraries can be screened for novel physiological, metabolic, and genetic options. Though long and labour-intensive, metagenomics is the most powerful environmental approach that provides prospects to get novel genes and novel biomolecules through the expression of genes from an uncultivated and unknown bacterium in a recipient host cell. Metagenomic information ought to contain DNA sequences for all the genes within the microorganism community

Cell therapies and regenerative medication boost the health of patients by repairing, replacing, or by creating broken cells within the body. Some elements of our bodies will repair themselves quite well when injured, while others dont repair in any respect. We cant develop an entire leg or arm; however, some animals will develop or regenerate whole body elements. Stem cells (SC) offer totally different. Despite the promise of embryonic stem cells, in several cases, adult or perhaps vertebrate stem cells give a lot of fascinating approach for clinical applications. Clinical applications in regenerative medication have increased tremendously throughout the last ten years. Regenerative medication revolutionizes the method to improve the health and quality of life by restoring, maintaining or enhancing tissue and functions of organs.

Clinical chemistry is usually involved with analysis of bodily fluids for diagnostic and therapeutic functions. It's an applied style of organic chemistry. There are currently several blood tests and clinical tests with intensive diagnostic capabilities. These are performed on any bodily fluid or plasma. The foremost common specimens tested in clinical chemistry are blood and Serum. Many various tests exist to check glucose, electrolytes, enzymes, hormones, lipids (fats), and proteins. By running tests on these samples, physicians will confirm patient conditions and potential diseases, and recommend a counselled treatment up. Clinical chemistry procedures create precise diagnoses, offer effective treatment choices and monitor a patients response to treatment.

Pharmacogenomics is the study of the gene effect on a persons response to medication. This comparatively new field combines pharmacological medicine and genetics to develop effective, safe medications and doses that may be tailored to a persons genetic makeup. Several medications presently accessible do not work a similar manner for everybody. Adverse drug reactions are a unit of big trouble for hospitalizations. With the data gained from the HGP, researchers are learning variations in genes have an effect on the bodys response to medications.

The field of pharmacogenomics continues to be in its infancy. Its use is presently quite restricted, however new approaches are in clinical trials. In future, pharmacogenomics can permit the tailored medication to treat health issues, as well as disorders, Alzheimer sickness, cancer, HIV/AIDS, and asthma.

DNA sequencing is the method of sequencing the base pairs of a DNA (As, Ts, Cs, and Gs). Sequencing a whole organisms DNA is a huge task. It needs breaking the DNA into several smaller items, sequencing the items, and collection of these sequences into one long "consensus."

These bases give the information on genotype and also the phenotype. Nucleotides aren't the sole determinants of phenotypes but are essential to their information. Every individual and organism feature a specific ester base sequence. DNA sequencing additionally underpins pharmacogenomics. This can be a comparatively new field that is leading to an individualized medication. Over a hundred and forty medication approved by the FDA currently by pharmacogenomic data in their labelling.

Translational medicine is defined as an interdisciplinary branch of the biomedical field. By using a highly collaborative approach Translational medicine is growing in biomedical research discipline and aims to expedite the discovery of new diagnostic tools and treatments. Within public health, translational medicine is focused on ensuring proven strategies for disease treatment and prevention. Translational medicine aims to improve human health and longevity by determining the relevance to human disease of novel discoveries in the biological sciences. Translational medicine is enhancing the efficiency of biomedical discovery and application. There are many compelling reasons to find cost-effective solutions to health care delivery.

Integrative Molecular Medicine covers novel findings in molecular, biological, and biomedicine research. The broad spectrum of Integrative Molecular Medicine includes rare and common disorders from diagnosis to treatment.

Molecular drugs strive to know traditional body functioning and illness pathological process at the molecular level which can enable researchers and physician-scientists to use that information within the style of specific molecular tools for illness identification, treatment, and prognosis. Integrative Molecular drugs (imMed) offers a scientific setting, which mixes basic and clinical analysis and offers a broad vary of advanced opportunities.

Medical doctors, patients, and health care providers consider the prevention of genetic diseases as an essential tool to improve the general health status of the population and the proportion of people suffering from genetics and genomics disease will increase by 65.2% by 2025. The top institutions researching in the related studies have been funded with 100 Billion Dollar worldwide. According to recent statistics, genetic diseases worldwide will double between 2012 and 2025. The market value of Molecular Medicine is $24 billion in 2015 and is expected to reach more than $100 billion by 2025.

Molecular Diagnostics Equipment market is influencing the

Molecular Diagnostics Equipment market is growing in -

witnessed growth in the -

followed by Molecular Diagnostics Equipment market in -

and the Middle East and Africa -

In 2015, the global molecular diagnostics market size was valued at USD 6,451.5 million and is anticipated to grow. In 2018, infectious diseases account for the largest share of the global molecular diagnostics market. Greater accuracy, portability, cost-effectiveness and Technological advancements enable molecular diagnostics to significantly drive the market.

Over the forecast period, the rising prevalence of infectious diseases and hospital-acquired infections are expected to drive market growth. Rise in cardiovascular, neurological, and genetic disorders is also expected to fuel market growth. Governments and different organizations Increase in funding for clinical studies in the molecular diagnosis space boost the market growth.

The hospitals and academic laboratories segment are expected to account for the largest share of the market in 2018.

The growth of the UAE diagnostic market can be attributed to the high prevalence of chronic and infectious diseases. WHO estimates of all deaths worldwide Chronic diseases account for approximately 60 %. Chronic diseases such as cancer, cardiovascular diseases, diabetes, and chronic respiratory diseases are responsible for 12%, 40%, 5%, and 5% of mortality in the United Arab Emirates. There has been a paradigm shift from traditional diagnostics to a new generation diagnostic, that works at the gene level. The inclusion of Advanced technologies such as genetic testing, molecular diagnostics, polymerase chain reaction (PCR), and next-generation sequencing (NGS) made it possible.

The major market players in the UAE molecular diagnostics market are :

The competition among manufacturers is increasing, with the increasing number of companies.

Genomics 2018

ME Conferenceshosted10thInternational Conference on Genomics & Molecular BiologyduringMay 21-23, 2018atBarcelona, Spainbased on the theme Advanced Approaches In Genomics and Molecular Biology.

Active participation and generous response was received from the Organizing Committee Members, scientists, researchers, as well as experts from Non-government organizations, and students from diverse groups who made this conference as one of the most successful and productive events in 2018 fromME Conferences.

The conference was marked with several workshops, multiple sessions, Keynote presentations, panel discussions and Poster sessions. We received active participation from scientists, young and brilliant researchers, business delegates and talented student communities representing more than 35 countries, who have driven this event into the path of success.

The conference was initiated with a warm welcome note by Honorable guests and the Keynote forum.The proceedings went through interactive sessions and panel discussions headed byhonorable ModeratorDr.Laila Alves Nahum, Ren Rachou Research Center, Brazilfor the conference.

The conference proceedings were carried out through various Scientific-sessions and plenary lectures, of which the following Speakers were highlighted asKeynote speakers:

Single point mutation of a gene creates mirror-image animals in freshwater gastropod:Reiko Kuroda, Tokyo University of Science, Japan

Evolutionary genomics to improve functional prediction of parasite genes and proteins:Laila Alves Nahum, Ren Rachou Research Center, Brazil

Big data in noncoding RNA and precision medicine:Runsheng Chen, Institute of Biophysics - CAS, China

Treatment of landfi ll leachate via advanced biological treatment technology:Ling Tau Chuan, University of Malaya, Malaysia

Biophysical signaling, systems biology and carcinogenesis:Sarah S Knox, West Virginia University School of Public Health USA

How does nucleoid complexity affect cell dimensions during the division process in bacillary bacteria: Arieh Zaritsky, Ben-Gurion University of the Negev, Israel

ME Conferenceshas taken the privilege of felicitating Genomics-2018 Organizing Committee, Keynote Speakers who supported for the success of this event.ME Conferences, on behalf of the Organizing Committee, congratulates the Best Poster awardees for their outstanding performance in the field of Genomics & Pharmacogenomics and appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavors.

Poster Judging was done byDr.Arieh Zaritsky, Ben-Gurion University of the Negev, Israel

We are also obliged to various delegate experts, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums. We sincerely thank theOrganizing Committee Membersfor their gracious presence, support, and assistance towards the success of Genomics-2018.

With the unique feedback from the conference,ME Conferenceswould like to announce the commencement of the "4th International Conference on Molecular Medicine and Diagnostics"duringJuly 15-16, 2019 in Abu Dhabi, UAE.

For More details visit:https://molecularmedicine.conferenceseries.com/

Read more:

Molecular Medicine Conference 2019 | Molecular Diagnostics ...

Rare diseases, which affect over 350million people worldwide and frequently go undiagnosed or misdiagnosed for years, suffer from sparse and dispersed medical knowledge leading to even rarer approved and effective therapeutic options for patients. A vast, unmet need for research and investment to advance diagnostic capabilities and therapeutic development must be confronted, despite the myriad of challenges faced. Several fundamental shifts are changing the landscape of rare diseases research and development, particularly with the application and extension of results to common diseases and the advancement of personalized medicine initiatives. Collaborative strategies that pool resources and knowledge are vital, including team science, research networks, novel funding models, shared knowledge platforms, and innovative regulatory frameworks. Importantly, patients are also increasingly involved as research partners and funders, pushing for open science and transparency, and breaking down data silos and geographical borders, often enabled by online platforms accessible from across the globe. The International Rare Diseases Research Consortium (IRDiRC), established in 2011, has been working diligently to unify stakeholders (e.g., funding bodies, companies, umbrella patient advocacy groups, researchers, and experts) to seek and drive solutions that aim to accelerate diagnosis and therapeutic development for rare diseases worldwide. Further and future advances will depend on continued collaborations and cooperation among stakeholders, working hand in hand with patients, and exponentially improving research and development efficiency. Critically, engagement with stakeholders from underrepresented populations and lessdeveloped countries must be prioritized, to enable all people living with a rare disease to receive an accurate diagnosis, care, and therapy.

Rare diseases: further and future advances for diagnostic capabilities and therapeutic development will depend on continued collaborations and cooperation among stakeholders, working handinhand with patients, and exponentially improving research and development efficiency.

EMBO Mol Med (2019) e10486

This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Go here to read the rest:

Home | EMBO Molecular Medicine

New! Nuclear Medicine Online Review Course

Take SNMMIs new online nuclear medicine review course. Updated for 2019, and covering the most essential topics in nuclear medicineyou'll gain the level of expertise you need to ace your exam! AMA PRA Category 1 credits available. Learn More

Access synchronized slides, audio and embedded video from 100 of the most popular sessions from SNMMIs 2018 Annual Meeting.Learn More

2018 Virtual Meeting Specialty PackagesPackages include:Cardiovascular, General Clinical Specialties, Neurosciences, Oncology and Therapy, and Technologist

The new Radiation Safety+ Review and Essentials program provides a comprehensive overview of all aspects of radiation safety for nuclear medicine technologists preparing to take the NMTCBs Radiation Safety Certification Examination.Learn More

CT+ Review and Essentials provides you with the comprehensive didactic education you need to succeed, whether you're looking to buildyour general CT knowledge, or preparing to sit for the ARRT (CT) and/or NMTCB (CT) exam(s).Learn More

SNMMI/ACNM MRI Case Reviews: AbdominalSNMMI and ACNM have partnered to bring you the first-ever set of online MRI teaching modules as an introduction to interpreting MRI.Learn More

Mid-Winter Meeting CT Case ReviewsThis offering provides a comprehensiveCT Case Reviewfor nuclear medicine professionals. Review and interpret up to 100 CT studies.Learn More

Annual Meeting CT/MRI Case ReviewsRecorded at the Annual Meeting, this online offering provides the opportunity to review and interpret 52 CT studies and 48 MRI case studies.Learn More

Free Journal SAM/CE accessis available exclusively for SNMMI Members. Take advantage of this great benefit and meet your certification requirements.Learn more

The PET Online Review Workshop is designed to prepare technologists for the NMTCB's PET Exam.Learn More

Visit link:

Society of Nuclear Medicine and Molecular Imaging (SNMMI)

The Department of Molecular Medicine in the Institute of Biotechnology (IBT) was established in 1994 to administer a program to train graduate students at the interface of basic and clinical sciences with an emphasis on biomedical research focused on discovering the molecular mechanisms underlying human disease and to serve as a platform for the development of novel treatment or prevention approaches. To date, our program has awarded over 120 doctoral degrees. Our graduates are placed in top-tier research universities and pharmaceutical companies across the United States and Europe. Our faculty have been successful in securing tens of millions of dollars from private and federal agencies including the National Institutes of Health, the National Science Foundation, and the Department of Defense.

Now also located in the South Texas Research Facility (STRF), we offer a research-oriented, interdisciplinary program of study in the areas of cancer and aging and their prevention. Specific areas of study include: cell (and hormone) signaling, gene expression, epigenetics, cell cycle and checkpoint controls, DNA damage repair and associated stress responses, and regulated protein turnover. Under new leadership, Dr. Tim Huang is expanding our research to include a Systems approach to molecular medicine that offers students an integrated training program spanning molecular and cellular biology, quantitative biology, computational biology, and genomics.

Our goal is to educate and train the next generation of graduate students who will change the face of biomedical research and invent new ways to treat and prevent human diseases.

Molecular Medicine in the News

Graduate School Launches a New Masters in Personalized Molecular Medicine

The Masters program in Personalized Molecular Medicine (PMM) will uniquely position new graduates to join the work force with the skills necessary to participate fully in the next generation of patient-powered research and treatment. The PMM program will train students in current personalized medicine approaches as well as teach students the knowledge and skills required to explore molecular medicine pathways that will be targeted in the future to expand and refine personalized treatment strategies.

For more information, click here.

Dr. Thomas Boyer awarded NIH grants to study uterine fibroids

Thomas G. Boyer, Ph.D., professor of molecular medicine at UT Health San Antonio, has received two related NIH R01 grants to study uterine leiomyomas, also called uterine fibroids.

The first grant was for $1.56 million; the most recent, a five-year award for $3.8 million, was a multi-PI grant to Dr. Boyer and Ayman Al-Hendy, M.D., Ph.D., a professor of obstetrics and gynecology at the University of Illinois at Chicago.

Both awards have been made possible by a productive, ongoing collaboration with Dr. Robert Schenken and his team in the Department of OB/GYN here at UT Health San Antonio, said Dr. Boyer.

For the rest of this story, please click here.

Recent Publications with High Impact Factors

Zhou Y, Gerrard DL, Wang J, Li T, Yang Y, Fritz AJ, Rajendran M, Fu X, Schiff R, Lin S, Frietze S, Jin VX. (2019) Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance. Nat Commun. 10(1):1522. PMID: 30944316

*#M. Morita, *N. Siddiqui, S. Katsumura, C. Rouya, O. Larsson, T. Nagashima, B. Hekmatnejad, A. Takahashi, H. Kiyonari, M. Zang, R. St-Arnaud, Y. Oike, V. Giguere, I. Topisirovic, M. Okada-Hatakeyama, T. #Yamamoto, N. #Sonenberg. A hepatic post-transcriptional network comprising of CCR4-NOT deadenylase and FGF21 maintains systemic metabolic homeostasis. Proc Natl Acad Sci USA, online (2019). *First authors and #Corresponding authors.

Li F, Wang Q, Seol JH, Che J, Lu X, Shim EY, Lee SE, Niu H. (2019) Apn2 resolves blocked 3' ends and suppresses Top1-induced mutagenesis at genomic rNMP sites. Nat Struct Mol Biol. 2019 Mar;26(3):155-163. doi: 10.1038/s41594-019-0186-1. Epub 2019 Feb 18.

*L. Hulea, *S.P. Gravel, *M. Morita, M. Cargnello, O. Uchenunu, Y.K. Im, C. Lehud, E.H. Ma, M. Leibovitch, S. McLaughlan, M.J. Blouin, M. Parisotto, V. Papavasiliou, C. Lavoie, O. Larsson, M. Ohh, T. Ferreira, C. Greenwood, G. Bridon, D. Avizonis, G. Ferbeyre, P. Siegel, R.G. Jones, W. Muller, J. Ursini-Siegel, J. St-Pierre, M. Pollak, I. Topisirovic. (2018) Translational and HIF-1-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides, Cell Metabolism. 2018 September 20. Online. *Co-First authors.

Seol JH, Holland C, Li X, Kim C, Li F, Medina-Rivera M, Eichmiller R, Gallardo IF, Finkelstein IJ, Hasty P, Shim EY, Surtees JA, Lee SE. (2018) Distinct roles of XPF-ERCC1 and Rad1-Rad10-Saw1 in replication-coupled and uncoupled inter-strand crosslink repair. Nat Commun. 2018 May 23;9(1):2025. doi:10.1038/s41467-018-04327-0. PubMed PMID: 29795289.

Patel MJ, Tripathy S, De Mukhopadhyay K, Wangjam T, Cabang AB, Morris J, Wargovich MJ. (2018) A Supercritical Co2 Extract of Neem Leaf (A. indica) and its Bioactive Liminoid, Nimbolide, Suppresses Colon Cancer in Preclinical Models by Modulating Pro-inflammatory Pathways. Mol Carcinogenesis. 2018 Apr 26. doi: 10.1002/mc.22832. [Epub ahead of print] PMID: 29697164

Park MJ, Shen H, Spaeth JM, Tolvanen JH, Failor C, Knudtson JF, McLaughlin J, Halder SK, Yang Q, Bulun SE, Al-Hendy A, Schenken RS, Aaltonen LA, Boyer TG. (2018) Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19. J Biol Chem. 2018 Mar 30; 293(13):4870-4882. doi: 10.1074/jbc.RA118.001725. Epub 2018 Feb 13.

Chen H, Shen F, Sherban A, Nocon A, Li Y, Wang H, Xu MJ, Rui X, Han J, Jiang B, Lee D, Li N, Keyhani-Nejad F, Fan JG, Liu F, Kamat A, Musi N, Guarente L, Pacher P, Gao B, Zang M. (2018) DEP domain-containing mTOR-interacting protein suppresses lipogenesis and ameliorates hepatic steatosis and acute-on-chronic liver injury in alcoholic liver disease. Hepatology. 2018 Feb 19. doi: 10.1002/hep.29849. [Epub ahead of print]

Recently Awarded Grants

UT Rising Stars AwardUniversity of Texas System, 12/1/2018, $250,000Masahiro Morita, Ph.D.

Dissecting the Interplay Between Proteasome Dysfunction, Proteostasis and Alzheimers DiseaseNIH - National Institute on Aging, 9/30/2018, $1,484,893Andrew Pickering, Ph.D.

Early Detection of Castration-Resistant Prostate Cancer by Assessing Interactions Between Circulating Tumor Cells and Accompanying Immune CellsDOD (CDMRP-PCRP), 9/1/18, $915,000Tim Huang, Ph.D., Maria Gaczynska, Ph.D.

A Novel Anti-BCR-ABL Approach for Leukemia TherapyCancer Prevention & Research Institute of Texas, 8/31/2018, $200,000Hai Rao, Ph.D.

Mechanisms of Error Prone Repair of DNA breaksNIH - National Institute of General Medical Sciences, 8/1/2018, $1,250,500Sang Eun Lee, Ph.D.

2018 Young Investigator AwardThe Max and Minnie Tomerlin Voelcker Fund, 6/30/2018, $450,000Myron Ignatius, Ph.D.

Molecular Basis of MED12 in the Pathogenesis of Uterine FibroidsNIH - National Institute of Child Health and Human Development, 5/1/2018, $1,562,323Thomas Boyer, Ph.D.

Combating Protein-misfolding DiseasesWilliam & Ella Owens Foundation of America, 3/1/18, $100,000Hai Rao, Ph.D.

Hypovitaminosis D Promotes MED12-associated Genomic Instability in Uterine FibroidsNIH National Institute of Child Health and Human Development, 2/15/18, $3,819,365Thomas Boyer, Ph.D.

Read the original here:

Molecular Medicine - Graduate School of Biomedical ...

About Proteomics and Bioinformatics Conference 2019 Proteomics and Bioinformatics Conference 2019

Welcome to the official website of 2019 13th International Conference & Expo on Proteomics and Bioinformatics (Proteomics Congress 2019). Proteomics Congress 2019 will be held in Zurich, Switzerland during July 11-12, 2019.

Theme: Global Perspectives in Proteomics and Bioinformatics

Proteomics Congress 2019 is one of the front platforms for disseminating latest research results and techniques in Proteomics Research, Mass spectrometry, Bioinformatics, Computational Biology, Biochemistry and Biophysics, Cardiac Proteomics and many more. This Conference will provide a vibrant atmosphere and venue for proteomics and bioinformatics scientists to present and publish their research results, investigations and studies.

In recent years, most areas of proteomics, bioinformatics, mass spectrometry, computational biology and medical informatics have experienced significant advances driven by computational techniques and novel research. Moreover these researches continue to be a vibrant research area with broadening applications and new emerging challenges. Proteomics Congress 2019 seeks original and high-quality contributions in the fields of Proteomics Research, Mass spectrometry, Protein Expression and Analysis, Bioinformatics, Computational Molecular Biology, Biochemistry and Biophysics, Glycobiology, Genetics and Genomics, Structural Biology, Structural Bioinformatics, Cardiac Proteomics, Advances in Proteomics and Bioinformatics and the related areas.Proteomics and Bioinformatics permits researchers to gauge physiological impacts and to screen for unfavorable responses to tranquilizes.

Why to attend??

Encounter the target market with members from across the globe, committed to learn about Proteomics and Bioinformatics. This is the best opportunity to outreach the largest gathering of participants from around the world. Conduct presentations, distribute and update knowledge about Proteomics and Bioinformatics, Mass spectrometry, Computational Biology and related areas and receive name recognition at this 2-days event. World-eminent speakers, most recent researches, latest treatment techniques and theadvanced updates in protein analysis, mass spectrometry, molecular diagnostics and devices are the principal features of this conference.

Target Audience:

Our Organization would be privileged to welcome the:

Highlights of latest advances on Proteomics and Bioinformatics 2019

Track: 1Proteomics from Discovery to Function

Proteomicsis an emerging field that has been highly enabled by the human genome project. Proteins are the products of genes, the machinery of the cells in our bodies. When genes are disrupted, theproteinsare also affected. Whenpathogensinfect us, causing disease, proteins play a key role in signaling the presence and ridding us of these invaders. Almost every process that occurs in our cells from the metabolization of simple sugar to the division of cells is dependent on proteins for smooth operation. In general,proteomicsseeks to detect and quantify as many proteins as possible.

Relevant Conferences:Proteomics Conferences|Proteomics Meetings | Bioinformatics Conferences | Proteomics and Bioinformatics Conferences 2019|Proteomics Conferences 2019 | Biochemistry Conferences | Proteomics Symposium | Bioinformatics Workshop

18th Human Proteome Organization World Congress September 15-18, 2019 Adelaide, Australia; VI International Caparica Congress on Analytical Proteomics 2019 July 08-11, 2019 Caparica, Portugal; 44th Lorne Conference on Protein Structure and Function February 10-14, 2019 Lorne Australia; Great Lakes Bioinformatics Conference May 19-22, 2019 Madison, USA; 9th International Conference on Bioscience, Biochemistry and Bioinformatics January 7-9, 2019 Singapore

Relevant Societies:Human Proteome Organization,European Proteomics Association(Eupa),Spanish Proteomics Society (Seprot),Netherlands Proteomic Platform(Npp),Japan Human Proteome Organisation(Jhupo),Italian Proteomic Association(Itpa),Portugese Proteomic Association(Rede Procura),Iranian Proteomic Society,Taiwan Proteomic Society(Tps),Austrian Proteomics Society,European Proteomics Association,British Mass Spectrometry Society,Belgian Mass Spectrometry Society,Danish Mass Spectrometry Society, Polish Bioinformatics Society, Helmholtz Network for Bioinformatics, Hellenic Society for Computational Biology and Bioinformatics, Israeli Society for Bioinformatics and Computational Biology, Bioinformatics Italian Society, EMBL - European Bioinformatics Institute

Track: 2Mass Spectrometry in Proteome Research

Mass spectrometry(MS) - based proteomics allows the sensitive and accurate quantification of almost complete proteomes of complex biological fluids and tissues. At the moment, however, the routinely usage of MS-based proteomics is prevented and complicated by the very complex work flow comprising sample preparation,chromatography, MS measurement followed by data processing and evaluation. The new technologies, products and assays developed byPrecision Proteomicscould help enabling and establishing mass spectrometry (MS) - based proteomics in academic andpharmaceutical proteomicsresearch as well as in clinical diagnostics.

Relevant Conferences:Proteomics Conferences|Proteomics Meetings | Bioinformatics Conferences | Proteomics and Bioinformatics Conferences 2019|Proteomics Conferences 2019 | Biochemistry Conferences | Proteomics Symposium | Bioinformatics Workshop

18th Human Proteome Organization World Congress September 15-18, 2019 Adelaide, Australia; VI International Caparica Congress on Analytical Proteomics 2019 July 08-11, 2019 Caparica, Portugal; 44th Lorne Conference on Protein Structure and Function February 10-14, 2019 Lorne Australia; Great Lakes Bioinformatics Conference May 19-22, 2019 Madison, USA; 9th International Conference on Bioscience, Biochemistry and Bioinformatics January 7-9, 2019 Singapore

Relevant Societies:Human Proteome Organization,European Proteomics Association(Eupa),Spanish Proteomics Society (Seprot),Netherlands Proteomic Platform(Npp),Japan Human Proteome Organisation(Jhupo),Italian Proteomic Association(Itpa),Portugese Proteomic Association(Rede Procura),Iranian Proteomic Society,Taiwan Proteomic Society(Tps),Austrian Proteomics Society,European Proteomics Association,British Mass Spectrometry Society,Belgian Mass Spectrometry Society,Danish Mass Spectrometry Society, Polish Bioinformatics Society, Helmholtz Network for Bioinformatics, Hellenic Society for Computational Biology and Bioinformatics, Israeli Society for Bioinformatics and Computational Biology, Bioinformatics Italian Society, EMBL - European Bioinformatics Institute

Track: 3Protein Expression and Analysis

Protein expressionrefers to the way in which proteins are synthesized, modified and regulated in living organisms. In protein research, the term can apply to either the object of study or the laboratory techniques required to manufacture proteins.Protein analysisis thebioinformaticsstudy of protein structure,protein interactionand function using database searches, sequence comparisons, structural and functional predictions.

Relevant Conferences:Proteomics Conferences|Proteomics Meetings | Bioinformatics Conferences | Proteomics and Bioinformatics Conferences 2019|Proteomics Conferences 2019 | Biochemistry Conferences | Proteomics Symposium | Bioinformatics Workshop

18th Human Proteome Organization World Congress September 15-18, 2019 Adelaide, Australia; VI International Caparica Congress on Analytical Proteomics 2019 July 08-11, 2019 Caparica, Portugal; 44th Lorne Conference on Protein Structure and Function February 10-14, 2019 Lorne Australia; Great Lakes Bioinformatics Conference May 19-22, 2019 Madison, USA; 9th International Conference on Bioscience, Biochemistry and Bioinformatics January 7-9, 2019 Singapore

Relevant Societies:Human Proteome Organization,European Proteomics Association(Eupa),Spanish Proteomics Society (Seprot),Netherlands Proteomic Platform(Npp),Japan Human Proteome Organisation(Jhupo),Italian Proteomic Association(Itpa),Portugese Proteomic Association(Rede Procura),Iranian Proteomic Society,Taiwan Proteomic Society(Tps),Austrian Proteomics Society,European Proteomics Association,British Mass Spectrometry Society,Belgian Mass Spectrometry Society,Danish Mass Spectrometry Society, Polish Bioinformatics Society, Helmholtz Network for Bioinformatics, Hellenic Society for Computational Biology and Bioinformatics, Israeli Society for Bioinformatics and Computational Biology, Bioinformatics Italian Society, EMBL - European Bioinformatics Institute

Track: 4Bioinformatics

Bioinformatics, an amalgam science that associates biological data with techniques for information storage, distribution, and analysis to support compound areas of scientific research, comprising biomedicine. It is nurtured by high-throughput data-generating experiments, including genomic sequence. Progress of effective algorithms for measuring sequence likeness is an important objective of bioinformatics. Thus is used to predict interfaces between proteins, given individual structures of the partners known as docking problem. Nevertheless, the ends of bioinformatics are integrative and are aimed at presuming out how combinations of diverse types of data can be used to apprehend natural phenomena, including organisms and disease.

Relevant Conferences:Proteomics Conferences|Proteomics Meetings | Bioinformatics Conferences | Proteomics and Bioinformatics Conferences 2019|Proteomics Conferences 2019 | Biochemistry Conferences | Proteomics Symposium | Bioinformatics Workshop

18th Human Proteome Organization World Congress September 15-18, 2019 Adelaide, Australia; VI International Caparica Congress on Analytical Proteomics 2019 July 08-11, 2019 Caparica, Portugal; 44th Lorne Conference on Protein Structure and Function February 10-14, 2019 Lorne Australia; Great Lakes Bioinformatics Conference May 19-22, 2019 Madison, USA; 9th International Conference on Bioscience, Biochemistry and Bioinformatics January 7-9, 2019 Singapore

Relevant Societies:Human Proteome Organization,European Proteomics Association(Eupa),Spanish Proteomics Society (Seprot),Netherlands Proteomic Platform(Npp),Japan Human Proteome Organisation(Jhupo),Italian Proteomic Association(Itpa),Portugese Proteomic Association(Rede Procura),Iranian Proteomic Society,Taiwan Proteomic Society(Tps),Austrian Proteomics Society,European Proteomics Association,British Mass Spectrometry Society,Belgian Mass Spectrometry Society,Danish Mass Spectrometry Society, Polish Bioinformatics Society, Helmholtz Network for Bioinformatics, Hellenic Society for Computational Biology and Bioinformatics, Israeli Society for Bioinformatics and Computational Biology, Bioinformatics Italian Society, EMBL - European Bioinformatics Institute

Track: 5 Computational Molecular Biology

Computational molecular biology brings together computational, statistical, experimental, and technological methods in order to further scientific discovery and develop new analytical tools for molecular biology.

Relevant Conferences:Proteomics Conferences|Proteomics Meetings | Bioinformatics Conferences | Proteomics and Bioinformatics Conferences 2019|Proteomics Conferences 2019 | Biochemistry Conferences | Proteomics Symposium | Bioinformatics Workshop

18th Human Proteome Organization World Congress September 15-18, 2019 Adelaide, Australia; VI International Caparica Congress on Analytical Proteomics 2019 July 08-11, 2019 Caparica, Portugal; 44th Lorne Conference on Protein Structure and Function February 10-14, 2019 Lorne Australia; Great Lakes Bioinformatics Conference May 19-22, 2019 Madison, USA; 9th International Conference on Bioscience, Biochemistry and Bioinformatics January 7-9, 2019 Singapore

Relevant Societies:Human Proteome Organization,European Proteomics Association(Eupa),Spanish Proteomics Society (Seprot),Netherlands Proteomic Platform(Npp),Japan Human Proteome Organisation(Jhupo),Italian Proteomic Association(Itpa),Portugese Proteomic Association(Rede Procura),Iranian Proteomic Society,Taiwan Proteomic Society(Tps),Austrian Proteomics Society,European Proteomics Association,British Mass Spectrometry Society,Belgian Mass Spectrometry Society,Danish Mass Spectrometry Society, Polish Bioinformatics Society, Helmholtz Network for Bioinformatics, Hellenic Society for Computational Biology and Bioinformatics, Israeli Society for Bioinformatics and Computational Biology, Bioinformatics Italian Society, EMBL - European Bioinformatics Institute

Track: 6Biochemistry and Biophysics

Biochemistry, sometimes called biological chemistry, is the study of chemical processes within and relating to living organisms. Biochemical processes give rise to the complexity of life. Biophysics is a bridge between biology and physics. Biophysics studies life at every level, from atoms and molecules to cells, organisms, and environments.

Relevant Conferences:Proteomics Conferences|Proteomics Meetings | Bioinformatics Conferences | Proteomics and Bioinformatics Conferences 2019|Proteomics Conferences 2019 | Biochemistry Conferences | Proteomics Symposium | Bioinformatics Workshop

18th Human Proteome Organization World Congress September 15-18, 2019 Adelaide, Australia; VI International Caparica Congress on Analytical Proteomics 2019 July 08-11, 2019 Caparica, Portugal; 44th Lorne Conference on Protein Structure and Function February 10-14, 2019 Lorne Australia; Great Lakes Bioinformatics Conference May 19-22, 2019 Madison, USA; 9th International Conference on Bioscience, Biochemistry and Bioinformatics January 7-9, 2019 Singapore

Relevant Societies:Human Proteome Organization,European Proteomics Association(Eupa),Spanish Proteomics Society (Seprot),Netherlands Proteomic Platform(Npp),Japan Human Proteome Organisation(Jhupo),Italian Proteomic Association(Itpa),Portugese Proteomic Association(Rede Procura),Iranian Proteomic Society,Taiwan Proteomic Society(Tps),Austrian Proteomics Society,European Proteomics Association,British Mass Spectrometry Society,Belgian Mass Spectrometry Society,Danish Mass Spectrometry Society, Polish Bioinformatics Society, Helmholtz Network for Bioinformatics, Hellenic Society for Computational Biology and Bioinformatics, Israeli Society for Bioinformatics and Computational Biology, Bioinformatics Italian Society, EMBL - European Bioinformatics Institute

Track: 7Glycobiology

Glycobiology is the study of the structure, function and biology of carbohydrates, also called glycans. Glycans are present in every living organism. Glycobiology is a rapidly growing field in biology, with relevance to biomedicine, biotechnology and basic research.

Relevant Conferences:Proteomics Conferences|Proteomics Meetings | Bioinformatics Conferences | Proteomics and Bioinformatics Conferences 2019|Proteomics Conferences 2019 | Biochemistry Conferences | Proteomics Symposium | Bioinformatics Workshop

18th Human Proteome Organization World Congress September 15-18, 2019 Adelaide, Australia; VI International Caparica Congress on Analytical Proteomics 2019 July 08-11, 2019 Caparica, Portugal; 44th Lorne Conference on Protein Structure and Function February 10-14, 2019 Lorne Australia; Great Lakes Bioinformatics Conference May 19-22, 2019 Madison, USA; 9th International Conference on Bioscience, Biochemistry and Bioinformatics January 7-9, 2019 Singapore

Relevant Societies:Human Proteome Organization,European Proteomics Association(Eupa),Spanish Proteomics Society (Seprot),Netherlands Proteomic Platform(Npp),Japan Human Proteome Organisation(Jhupo),Italian Proteomic Association(Itpa),Portugese Proteomic Association(Rede Procura),Iranian Proteomic Society,Taiwan Proteomic Society(Tps),Austrian Proteomics Society,European Proteomics Association,British Mass Spectrometry Society,Belgian Mass Spectrometry Society,Danish Mass Spectrometry Society, Polish Bioinformatics Society, Helmholtz Network for Bioinformatics, Hellenic Society for Computational Biology and Bioinformatics, Israeli Society for Bioinformatics and Computational Biology, Bioinformatics Italian Society, EMBL - European Bioinformatics Institute

Track: 8 Genetics and Genomics

Genetics is the study of heredity, or how the characteristics of living organisms are transmitted from one generation to the next via DNA, the substance that comprises genes, the basic unit of heredity. Genetics involves the study of specific and limited numbers of genes, or parts of genes, that have a known function. In biomedical research, scientists try to understand how genes guide the bodys development, cause disease or affect response to drugs. Genomics, in contrast, is the study of the entirety of an organisms genes called the genome. Using high-performance computing and math techniques known as bioinformatics, genomics researchers analyze enormous amounts of DNA-sequence data to find variations that affect health, disease or drug response. In humans that means searching through about 3 billion units of DNA across 23,000 genes. Genomics is a much newer field than genetics and became possible only in the last couple of decades due to technical advances in DNA sequencing and computational biology.

Relevant Conferences:Proteomics Conferences|Proteomics Meetings | Bioinformatics Conferences | Proteomics and Bioinformatics Conferences 2019|Proteomics Conferences 2019 | Biochemistry Conferences | Proteomics Symposium | Bioinformatics Workshop

18th Human Proteome Organization World Congress September 15-18, 2019 Adelaide, Australia; VI International Caparica Congress on Analytical Proteomics 2019 July 08-11, 2019 Caparica, Portugal; 44th Lorne Conference on Protein Structure and Function February 10-14, 2019 Lorne Australia; Great Lakes Bioinformatics Conference May 19-22, 2019 Madison, USA; 9th International Conference on Bioscience, Biochemistry and Bioinformatics January 7-9, 2019 Singapore

Relevant Societies:Human Proteome Organization,European Proteomics Association(Eupa),Spanish Proteomics Society (Seprot),Netherlands Proteomic Platform(Npp),Japan Human Proteome Organisation(Jhupo),Italian Proteomic Association(Itpa),Portugese Proteomic Association(Rede Procura),Iranian Proteomic Society,Taiwan Proteomic Society(Tps),Austrian Proteomics Society,European Proteomics Association,British Mass Spectrometry Society,Belgian Mass Spectrometry Society,Danish Mass Spectrometry Society, Polish Bioinformatics Society, Helmholtz Network for Bioinformatics, Hellenic Society for Computational Biology and Bioinformatics, Israeli Society for Bioinformatics and Computational Biology, Bioinformatics Italian Society, EMBL - European Bioinformatics Institute

Track: 9 Structural Biology

Structural biology is the study of the molecular structure and dynamics of biological macromolecules, particularly proteins and nucleic acids, and how alterations in their structures affect their function. Structural biology incorporates the principles of molecular biology, biochemistry and biophysics.

Relevant Conferences:Proteomics Conferences|Proteomics Meetings | Bioinformatics Conferences | Proteomics and Bioinformatics Conferences 2019|Proteomics Conferences 2019 | Biochemistry Conferences | Proteomics Symposium | Bioinformatics Workshop

18th Human Proteome Organization World Congress September 15-18, 2019 Adelaide, Australia; VI International Caparica Congress on Analytical Proteomics 2019 July 08-11, 2019 Caparica, Portugal; 44th Lorne Conference on Protein Structure and Function February 10-14, 2019 Lorne Australia; Great Lakes Bioinformatics Conference May 19-22, 2019 Madison, USA; 9th International Conference on Bioscience, Biochemistry and Bioinformatics January 7-9, 2019 Singapore

Relevant Societies:Human Proteome Organization,European Proteomics Association(Eupa),Spanish Proteomics Society (Seprot),Netherlands Proteomic Platform(Npp),Japan Human Proteome Organisation(Jhupo),Italian Proteomic Association(Itpa),Portugese Proteomic Association(Rede Procura),Iranian Proteomic Society,Taiwan Proteomic Society(Tps),Austrian Proteomics Society,European Proteomics Association,British Mass Spectrometry Society,Belgian Mass Spectrometry Society,Danish Mass Spectrometry Society, Polish Bioinformatics Society, Helmholtz Network for Bioinformatics, Hellenic Society for Computational Biology and Bioinformatics, Israeli Society for Bioinformatics and Computational Biology, Bioinformatics Italian Society, EMBL - European Bioinformatics Institute

Track: 10Structural Bioinformatics

Structural bioinformatics is the branch of bioinformatics which is related to the analysis and prediction of the three-dimensional structure of biological macromolecules such as proteins, RNA, and DNA.

Relevant Conferences:Proteomics Conferences|Proteomics Meetings | Bioinformatics Conferences | Proteomics and Bioinformatics Conferences 2019|Proteomics Conferences 2019 | Biochemistry Conferences | Proteomics Symposium | Bioinformatics Workshop

18th Human Proteome Organization World Congress September 15-18, 2019 Adelaide, Australia; VI International Caparica Congress on Analytical Proteomics 2019 July 08-11, 2019 Caparica, Portugal; 44th Lorne Conference on Protein Structure and Function February 10-14, 2019 Lorne Australia; Great Lakes Bioinformatics Conference May 19-22, 2019 Madison, USA; 9th International Conference on Bioscience, Biochemistry and Bioinformatics January 7-9, 2019 Singapore

Relevant Societies:Human Proteome Organization,European Proteomics Association(Eupa),Spanish Proteomics Society (Seprot),Netherlands Proteomic Platform(Npp),Japan Human Proteome Organisation(Jhupo),Italian Proteomic Association(Itpa),Portugese Proteomic Association(Rede Procura),Iranian Proteomic Society,Taiwan Proteomic Society(Tps),Austrian Proteomics Society,European Proteomics Association,British Mass Spectrometry Society,Belgian Mass Spectrometry Society,Danish Mass Spectrometry Society, Polish Bioinformatics Society, Helmholtz Network for Bioinformatics, Hellenic Society for Computational Biology and Bioinformatics, Israeli Society for Bioinformatics and Computational Biology, Bioinformatics Italian Society, EMBL - European Bioinformatics Institute

Track: 11Cardiac Proteomics

Cardiac proteomics is a scientific field spearheaded by the Lundby group. Cardiac proteomics allows for unbiased investigations of protein and signaling changes taking place in cardiac tissue. In the Lundby group cardiac proteomics is applied to gain molecular insights into regulatory processes in the heart.

Relevant Conferences:Proteomics Conferences|Proteomics Meetings | Bioinformatics Conferences | Proteomics and Bioinformatics Conferences 2019|Proteomics Conferences 2019 | Biochemistry Conferences | Proteomics Symposium | Bioinformatics Workshop

18th Human Proteome Organization World Congress September 15-18, 2019 Adelaide, Australia; VI International Caparica Congress on Analytical Proteomics 2019 July 08-11, 2019 Caparica, Portugal; 44th Lorne Conference on Protein Structure and Function February 10-14, 2019 Lorne Australia; Great Lakes Bioinformatics Conference May 19-22, 2019 Madison, USA; 9th International Conference on Bioscience, Biochemistry and Bioinformatics January 7-9, 2019 Singapore

Relevant Societies:Human Proteome Organization,European Proteomics Association(Eupa),Spanish Proteomics Society (Seprot),Netherlands Proteomic Platform(Npp),Japan Human Proteome Organisation(Jhupo),Italian Proteomic Association(Itpa),Portugese Proteomic Association(Rede Procura),Iranian Proteomic Society,Taiwan Proteomic Society(Tps),Austrian Proteomics Society,European Proteomics Association,British Mass Spectrometry Society,Belgian Mass Spectrometry Society,Danish Mass Spectrometry Society, Polish Bioinformatics Society, Helmholtz Network for Bioinformatics, Hellenic Society for Computational Biology and Bioinformatics, Israeli Society for Bioinformatics and Computational Biology, Bioinformatics Italian Society, EMBL - European Bioinformatics Institute

Track: 12Advances in Proteomics and Bioinformatics

Proteomics & Bioinformatics deals with all aspects of translational proteomics, application of proteomic technology to all aspects of clinical research and molecular medicine and identification of proteins that are involved in pathological process which results in understanding the how a disease can lead to altered protein expression and it analysis the complete study of the proteins produced and expressed in the biological systems of an organism at a particular period of time..

Relevant Conferences:Proteomics Conferences|Proteomics Meetings | Bioinformatics Conferences | Proteomics and Bioinformatics Conferences 2019|Proteomics Conferences 2019 | Biochemistry Conferences | Proteomics Symposium | Bioinformatics Workshop

18th Human Proteome Organization World Congress September 15-18, 2019 Adelaide, Australia; VI International Caparica Congress on Analytical Proteomics 2019 July 08-11, 2019 Caparica, Portugal; 44th Lorne Conference on Protein Structure and Function February 10-14, 2019 Lorne Australia; Great Lakes Bioinformatics Conference May 19-22, 2019 Madison, USA; 9th International Conference on Bioscience, Biochemistry and Bioinformatics January 7-9, 2019 Singapore

Relevant Societies:Human Proteome Organization,European Proteomics Association(Eupa),Spanish Proteomics Society (Seprot),Netherlands Proteomic Platform(Npp),Japan Human Proteome Organisation(Jhupo),Italian Proteomic Association(Itpa),Portugese Proteomic Association(Rede Procura),Iranian Proteomic Society,Taiwan Proteomic Society(Tps),Austrian Proteomics Society,European Proteomics Association,British Mass Spectrometry Society,Belgian Mass Spectrometry Society,Danish Mass Spectrometry Society, Polish Bioinformatics Society, Helmholtz Network for Bioinformatics, Hellenic Society for Computational Biology and Bioinformatics, Israeli Society for Bioinformatics and Computational Biology, Bioinformatics Italian Society, EMBL - European Bioinformatics Institute

Summary:

Proteomics attribute to the study of proteomes, but is also used to characterize the techniques used to determine the complete set of proteins of an organism or system, such as protein purification and MS. Proteomics is a developing field that has been deeply enabled by the human genome project. Proteins which are the products of genes, the machinery of the cells in our bodies. When genes are disturbed, the proteins are also damaged. When pathogens infect us, causing disease, proteins play a major role in signaling the presence & ridding us of these invaders. Almost every process which that occurs in our cells from the metabolization of clean sugar to the distribution of cells is dependent on proteins for smooth operation. In general, proteomics seeks to distinguish & quantify as many proteins as possible likewise Bioinformatics is an interdisciplinary field that develops methods and software tools for understanding biological data. As an interdisciplinary field of science, bioinformatics combines biology, computer science, information engineering, mathematics and statistics to analyze and interpret biological data. Bioinformatics has been used for in silico analyses of biological queries using mathematical and statistical techniques.

Importance & Scope:

There are numerous advances in this proteomics innovation, especially in the field of sub-atomic science. New proteomics and genomics advancements and creations could be utilized for ailment particular biomarker revelation and to screen tolerant reaction to the treatment. Proteomics might likewise set up new, atomic order of the malady. Applying genomic and proteomic strategies to body liquids (serum, cerebrospinal liquid, pee, and so on.) and tissue concentrates would put profitable goal diagnostic force in the hands of the clinician however approval of those techniques is an imperative issue. The quick extension of the analytic apparatuses taking into account advancements in proteomic and genomic advances can be essential for the improvement of customized solution. As a science that studies interactions between the molecular components that carry out the various biological processes in living cells, an important idea in molecular biology states that information flow in organisms follows a one-way street: Genes are transcribed into RNA, and RNA is translated into proteins. Bioinformatics uses improvements in the area of computer science, information science, computer and information technology, communication technology to solve complex problems in life.

Why Zurich, Switzerland?

Europe is one such region which encompasses the major share of the Proteomics and Bioinformatics research. Zurich being one of the most advanced European economies is bound to hold the chief share in Europes Proteomics and molecular medicine market. Further as EU expands the research, export and trading relations are bound to enhance.

Major Proteomics and Bioinformatics Related Associations around the Globe:

Proteomics and Bioinformatics Market Projection:

The globalproteomics marketis expected to reach over USD 24.8 billion by 2024 according to a new report by Grand View Research, Inc. The introduction of technology-enabled proteomics products is one of the high-impact rendering drivers for the proteomics market growth. These products find extensive applications in drug discovery, diagnostic services, and many other research areas. The increasing market penetration of these technologies, such as ESI-LC-MS (electrospray ionization liquid chromatography mass spectrometry), is expected to serve as a driver of this market.

Proteomics Market By Product, USD Million, 2013 - 2024

The global bioinformatics market is projected to reach USD 13.50 billion in 2023 from USD 7.73 billion in 2018, at CAGR of 14.5%. Growing demand for nucleic acid and protein sequencing, initiatives from government and private organizations, growing applications of bioinformatics, and the increasing number of collaborations between companies and research institutes are the major factors driving the growth of the market.

Proteomics Congress 2018

Conference Series LLC Ltdtakes a great pride in announcing the 12th International Conference & Expo on Proteomics and Molecular Medicine(Proteomics Congress 2018) which was held in Dublin, Ireland, during 26-28 November, 2018.

Proteomics Congress 2018 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various newfangled topics related to the field of proteomics and molecular medicine. The extremely illustrious conference hosted by Conference Series LLC Ltd was marked with the attendance of young and brilliant researchers, business delegates and talented student communities representing more than 30 countries around the world.

The conference aimed a parallel rail with theme Solving problems in Proteomics, Biology and Medicine. The meeting engrossed a vicinity of cognizant discussions on novel subjects like Mass spectrometry in Proteome Research, Protein Expression and Analysis, Proteomics from Discovery to Function, Molecular Medicine and Diagnostics, to mention a few. The three days event implanted a firm relation of upcoming strategies in the field of Proteomics, Molecular Medicine, Bioinformatics and Mass Spectrometry Technology with the scientific community. The conceptual and applicable knowledge shared, will also foster organizational collaborations to nurture scientific accelerations.

The Organizing Committee would like to thank the moderator Dr. Magnus S. Magnusson from University of Iceland, Iceland for his contributions which resulted in smooth functioning of the conference.

The conference was embarked with an opening ceremony followed by a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The highlights of the conference were the keynote forum by prominent scientists,Klaus Ammann,University of Bern, Switzerland;Magnus S. Magnusson,University of Iceland, Iceland;Graham Ball,CompanDX, UK;Henry M. Sobell,University of Rochester, USA;Frdric Fonlut, Biotechnology Consulting, Spain; gave their fruitful contributions in the form of highly informative presentations and made the conference a top notch one.

Conference Series LLC Ltdis prerogative to thank the Organizing Committee Members, Keynote speakers, Chair and Co-chairs on transcribing the plenary sessions and Symposium in a diversified and variegate manner to make this conference an enviable artifact.

Conference Series LLC Ltdwould sincerely extend our thanks to our chair persons Dr. Laszlo Takacs, Biosystems International Kft., Hungary and Dr. Graham Ball, CompanDX, UK who supported us by chairing the scientific sessions.

Conference Series LLC Ltdoffers its heartfelt appreciation to the collaborators European Biotechnology Network, Bilkent Genetik Toplulugu, Malaysian Biotechnology Information Center, Swiss Biotech Association & Human Behaviour Laboratory who supported the conference in every aspect for the awe-inspiring exhibition at the venue. We also express our sincere thanks to all the media partners for the promotion of our event to glory.

Conference Series LLC Ltdcongratulates the best poster award winnerMs. Inga Jamrozek,Intercollegiate Faculty of Biotechnology UG MUG, Poland. We would also like to thank Dr. Klaus Ammann, University of Bern, Switzerland who supported us by evaluating the posters.

We once again thank all the participants for their wonderful contribution towards the event which helped us for successful accomplishment of this event.

Conference Series LLC Ltd 12th International Conference & Expo on Proteomics and Molecular Medicine would not have been successful if it has not been supported by international, multi-professional steering committee and coordination of theJournal of Proteomics & Bioinformatics, Journal of Pharmacogenomics & Pharmacoproteomics & Journal of Data Mining in Genomics & Proteomics.

After the successful completion of eleven consecutive conferences we are overwhelmed to announce our next upcoming conferences which are going to be held in Europe is the 13th International Conference and Expo on Proteomics and Bioinformatics which is going to be held during July 11-12, 2019 in Zurich, Switzerland.

Conference Series llc LTDtakes a great pride in announcing the 9thInternational Conference & Expo on Proteomics and Molecular Medicine(Proteomics Congress 2017) which was held in Paris, France, during 13-15 November, 2017.

Proteomics Congress 2017 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various newfangled topics related to the field of proteomics and molecular medicine. The extremely illustrious conference hosted byConference Series llc LTDwas marked with the attendance of young and brilliant researchers, business delegates and talented student communities representing more than 30 countries around the world.

The conference aimed a parallel rail with theme Novel Advancements in Proteomics and Molecular Medicine. The meeting engrossed a vicinity of cognizant discussions on novel subjects like Mass spectrometry in Proteome Research, Protein Expression and Analysis, Proteomics from Discovery to Function, Molecular Medicine and Diagnostics, to mention a few. The three days event implanted a firm relation of upcoming strategies in the field of Proteomics, Molecular Medicine, Bioinformatics and Mass Spectrometry Technology with the scientific community. The conceptual and applicable knowledge shared, will also foster organizational collaborations to nurture scientific accelerations.

The Organizing Committee would like to thank the moderatorsDr. Oliva Petrafrom Sanofi Genzyme, USA,Dr. Marwa Eltoweissy, University of Gttingen, Germany for their contributions which resulted in smooth functioning of the conference.

The conference was embarked with an opening ceremony followed by a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The highlights of the conference were the keynote forum by prominent scientists,Boris Zaslavsky,Cleveland Diagnostics, USA;Bin Huang,Kaohsiung Medical University, Taiwan;Judit Ovdi,Hungarian Academy of Sciences, Hungary;Jarrod A Marto,Harvard Medical School, USA;Magnus S Magnusson, University of Iceland, Iceland; gave their fruitful contributions in the form of highly informative presentations and made the conference a top notch one.

Read this article:

Molecular Medicine Conferences 2018 - Proteomics Conference

You take both research projects below.

You complete a mini research project to equip you with the skills and understanding required to complete the six-month research project. The mini research project is taken over two and a half weeks, either in pairs or groups of three, providing experience of a hands-on approach to experimental work.

In a set frame of scientific theme and of available samples, equipment and reagents, you first define your working hypothesis. You subsequently answer your framed scientific questions by researching and developing the most adapted protocols, performing all the experimental work, computing and critically analysing your own data.

The mini research project will be undertaken in dedicated teaching laboratories at the Hammersmith Campus.

You complete your six-month research project in the Faculty of Medicine at Hammersmith, St Mary's, Charing Cross or South Kensington campuses (subject to approval).

Each student will be assigned a research project and will be selectedon the basis that you can reasonably be expected to make an original contribution to the chosen area of research within the time period allotted.

You are provided with training in academic research and acquisition of practical skills, including the design of a research project, planning of experiments, dealing with practical problems, recording, presenting and analysing data. Time will be allocated towards the end of the project period to write a report of 10,000 words.

Read the original post:

MSc Molecular Medicine | Study | Imperial College London

What is Personalized Medicine?

Every individuals disease is different. Personalized medicine strives to provide the right medicine for the right patient with the lowest toxicity. Personalized cancer therapy using proteomics involves molecular profiling of the patients cancer cells to map the susceptible drug targets and thereby guide therapy. Research, like that being done by the Center for Applied Proteomics and Molecular Medicine, provides strategies for personalized treatment with the goal of providing physicians key missing molecular information about the disease in each of their patients and improving the quality of life for patients.

The Center for Applied Proteomics and Molecular Medicines mission is to: a) create new technologies and make basic science discoveries in the field of disease pathogenesis b) apply these discoveries and technologies to create and implement strategies for disease prevention, early diagnosis and individualized therapy. The primary emphasis of our disease research is cancer, but new technologies developed in the center are being applied to a number of important human diseases including cardiovascular disease, diabetes, and obesity, as well as liver, ocular, neurodegenerative and infectious diseases.

The Scientists at George Mason University have developed a nanotechnology that for the first time can measure a sugar molecule in urine that identifies tuberculosis with high sensitivity and specificity, setting the stage for a rapid, highly accurate and far less-invasive urine test of the disease that could potentially prove to be the difference between life and death in many underdeveloped parts of the world.The international team led by George Masons Alessandra Luchini and Lance Liotta report in Science Translational Magazine that a sugar molecule called LAM, which comes from the surface of the tuberculosis bacteria, can be measured in the urine of all patients with active tuberculosis regardless of whether they have a simultaneous infection with another pathogen (e.g. HIV). The more severe the disease, the higher the sugar concentration in the urine, said Luchini, an associate professor in Masons College of Science.Current methods of detection skin tests, blood tests and chest X-rays are often very expensive and not always available in rural settings in lesser developed parts of the world. Urine is considered an ideal body fluid for a TB test because it can be easily and noninvasively collected.We can measure now what could never be measured before, said Liotta, co-director of Masons Center for Applied Proteomics and Molecular Medicine.

The Side-Out Metastatic Breast cancer trial was announced at the annual meeting of the American Society of Clinical Oncology (ASCO) and is expected to expand into phase two this month.

ASCO Poster Presentation

The pilot study was the first of its kind to utilize novel protein activation mapping technology along with the genomic fingerprint of cancer as a way to find the most effective treatment. Results indicate that while prior standard chemotherapy failed the 25 women who participated in the 2.5 year pilot study, nearly half of the patients enrolled in the Side-Out trail had at least a 30 percent increase in progression-free survival.

This molecular approach creates opportunities for new therapies. For example, if a breast tumor shares the same protein pathway activation shared with lung cancer, then the drug developed to hit that target for lung cancer can be used now for breast cancer. The pilot study included only FDA-approved drugs currently on the market. Additional studies are expected to fold in new drugs as they become available with experimental drug.

Hear what patients and a treating physician has to say: Funded by Volleyball Tournaments, Breast Cancer Pilot Study Succeeds

Based on the results of this trial, CAPMM and the Side-Out Foundation are expanding this study to a new trial that is set to launch within the next month.

Follow this link:

Center for Applied Proteomics and Molecular Medicine

Holiday Inn Macao Cotai Central Sands Cotai Central, Cotai Strip, Taipa, Macau SAR, China

Program Timetable (PDF version) is available. (FINAL, updated on Oct 26)

Registration Time:

IEEE-NANOMED is one of the premier annual events organized by the IEEE Nanotechnology Council to bring together physicians, scientists and engineers alike from all over the world and every sector of academy and industry, working at advancement of basic and clinical research in medical and biological sciences using nano/molecular and engineering methods. IEEE-NANOMED is the conference where practitioners will see nano/molecular medicine and engineering at work in both their own and related fields, from essential and advanced scientific and engineering research and theory to translational and clinical research.

Conference Theme:

Authors are also invited to submit results to a special issue of the journal Micromachines (impact factor 1.295), on the topic of Microdevices and Microsystems for Cell Manipulation. More information on the special issue and paper submission can be found here:http://www.mdpi.com/journal/micromachines/special_issues/cell_manipulation

Authors are also invited to submit results to a special issue of the journal Micromachines (impact factor 1.295), on the topic of MEMS/NEMS for Biomedical Imaging and Sensing. More information on the special issue and paper submission can be found here:http://www.mdpi.com/journal/micromachines/special_issues/MEMS_biomedical_imaging_sensing

Continued here:

IEEE-NANOMED 2016 The 10th IEEE International Conference ...